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Abstract
An investigation into the mechanism of proteasome dysfunction in
neurodegenerative disease and the biological impact of proteasome
hyperactivation in C. elegans
Raymond T. Anderson
Aging is an inevitable process that occurs as humans grow older. It is characterized by
the chronological accumulation of cellular damage over time leading to functional decline
as an organism grows older. Several processes are thought to contribute to the aging
phenomenon, but one of the most prolific of these is the disruption of protein homeostasis
(proteostasis). The collapse of proteostasis can lead to accelerated aging and the
development of age-related diseases including devastating neurodegenerative diseases
(NDs) like Alzheimer and Parkinson disease. Virtually all NDs are characterized by the
buildup of proteins in and around neurons resulting in neuronal death or loss of function.
It is thought that this buildup of misfolded/damaged proteins is at least partially due to
loss of protein degradation capacity of the ubiquitin proteasome system (UPS) as its
impairment has been reported in essentially all NDs. It is hypothesized that the presence
of specific protein oligomers in various NDs mediate this proteasomal inhibition.
Determining the mechanism of oligomer mediated proteasome inhibition is the focus of
the first study reported here. We show that three different proteins from Alzheimer,
Parkinson, and Huntington disease that misfold and oligomerize into a shared threedimensional structure potently impair the proteasome by stabilizing the closed-gate
conformation. These oligomers were unable to inhibit a mutant proteasome construct with
a constitutively open entry pore. Based on these findings, we sought to introduce the
open-gate proteasome construct into a model organism, which is the focus of study two
in this dissertation. Using CRISPR to introduce this mutation in the germline of
Caenorhabditis elegans (C. elegans), we successfully generated the first animal model
that endogenously expresses a hyperactive, open-gate proteasome. As expected, the
proteasome showed enhanced degradation of peptides, unstructured proteins, and a
folded ubiquitinated protein. Aside from a substantial decrease in fecundity, these
nematodes showed significantly increased lifespan and a significant resistance to
oxidative and proteotoxic stress. The results show that introducing a constitutively active
proteasome into a multicellular organism is feasible and suggests targeting the
proteasome gating mechanism as a valid approach for future age-related disease
research efforts in mammals.
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Proteostasis Collapse in Neurodegenerative Disease and Aging:
A Literature Review
Alzheimer disease is devastating and progressive neurodegenerative disease that
causes severe memory loss, personality changes, and eventually leads to death. As of
2022, approximately 6.5 million (10.7%) US Americans aged 65 years and older are living
with the disease, and this number is predicted to grow to 13.8 million by 2060 if a viable
intervention remains elusive1,2. AD is uniquely characterized by the presence of specific
protein aggregation deposits: extracellular amyloid β “plaques” and intracellular
neurofibrillary “tangles” (tau). The presence of protein aggregates is not unique to AD as
protein

misfolding

and

accumulation

are

characteristic

of

virtually

all

other

neurodegenerative diseases including Parkinson disease (PD), Huntington disease (HD),
and amyotrophic lateral sclerosis (ALS) (Fig. 1)3. The main risk factor for developing many
of these protein misfolding diseases is age4–6; thus, they are often collectively labeled
age-related diseases. This review will describe the relationships between the various
hallmarks of aging and protein homeostasis (proteostasis). It will also outline cellular
mechanisms that help maintain proteostasis and various approaches used to increase
proteasome mediated protein degradation.

A

B

C

D

Figure 1. Characteristic ND neuropathological
lesions. All are labeled with antibodies as indicated.
A) AD, neuritic plaque labeled for Aβ (cerebral
cortex). B) HD, intranuclear inclusion labeled for
huntingtin (cerebral cortex). C) PD, Lewy bodies
labeled for α-synuclein (substantial nigra). D) ALS,
cytoplasmic skein of neurofilaments labeled with
neurofilament (medulla oblongata). Figure adapted
from: Ross CA, Poirier MA. Protein aggregation and
neurodegenerative disease. Nat Med. 2004;10
Suppl: S10-S17. doi:10.1038/nm1066
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Relationship between hallmarks of aging and proteostasis
Aging is an inevitable biological process that occurs in all multicellular organisms over
time (except for select species including the immortal jellyfish, Turritopsis dohrnii7) and is
characterized by the chronological accumulation of cellular damage over time leading to
functional decline as an organism grows older8. Aging occurs naturally in humans but is
considered a key risk factor for many chronic diseases present in older populations. The
cause of cellular damage accumulation with age is understood to be incredibly complex,
but nine key “hallmarks” of aging have been identified and outlined in a recent
comprehensive review4. They include genomic instability, telomere attrition, epigenetic
alterations, mitochondrial dysfunction, cellular senescence, deregulated nutrient-sensing,
stem cell exhaustion, altered intercellular communication, and loss of proteostasis (Fig.
2)4. While aggravating any
one of these hallmarks can
cause a variety of deleterious
effects and accelerate aging,
they are almost all linked to
protein aggregation in some
way. The discussion below
will discuss the links between
proteostasis and the genetic
hallmarks,

mitochondrial

dysfunction, and deregulated
Figure 2. Graphical illustration of the nine hallmarks of aging.
doi:10.1016/j.cell.2013.05.039

nutrient sensing.
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Genomic Instability
Genomic Instability and loss of proteostasis are intricately connected because proteins
and DNA constantly interact with each other in a normal and healthy cell. Genomic
instability can be characterized by the accumulation of unrepaired DNA damage overtime
that can result in mutations and even chromosomal rearrangements9. Every time DNA is
replicated, there is a chance for DNA damage to occur, which is usually corrected by a
vast network of DNA repair pathways and damage-induced signaling cascades10.
Although this repair network typically restores DNA damage just fine, DNA can sometimes
be repaired improperly resulting in an accumulation of DNA damage over time11. Several
early studies in the 1990s and early 2000s have described increased DNA damage
present in several NDs characterized by protein accumulation including AD, HD, PD, and
ALS12–18. These studies were largely corelative in nature, but since then, causative
relationships between protein aggregation and genomic instability have been described
and reviewed in detail19.

Some individual ND associated proteins including tau, amyloid-β, huntingtin, α-synuclein
and their aggregates have been shown to cause DNA strand breaks and impairments in
DNA repair mechanisms leading to genomic instability20–22. The reason for this genomic
instability is unclear but could be caused by aggregate induced mitochondria
dysfunction23. For example, aggregated α-synuclein24, SOD125, TDP-4326, Huntingtin27,
and Aβ28 have all been shown to cause mitochondria derived oxidative stress that can
lead to genomic instability. Extensive oxidative DNA damage can lead to programed cell
death (PCD) which begins with the degradation of higher order chromatin structures.
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Under conditions of transient stress, PCD can be reversible29,30. However, even transient
chromatin degradation could lead to significant DNA alterations causing loss of function
of an expressed protein or loss of expression entirely. More detailed proposed
mechanisms of higher order chromatin degradation in relation to NDs have been reviewed
previously31.

In addition, aggregates are sticky complexes that could also sequester essential DDR
proteins32. For example, a 2015 study reported decreased levels of BRCA1, an important
DDR protein, in the brains of AD patients and a transgenic AD mouse model26. When
they experimentally removed BRCA1 from mouse neurons, they observed significantly
elevated DNA damage compared to age matched controls. It was later discovered in 2019
that BRCA1 and another DDR protein, P53 binding protein, were present in tau
aggregates of AD, Pick’s disease, and frontotemporal dementia tissues suggesting
sequestration of these DDR proteins could be involved in disease pathogenesis33. A
similar depletion of DDR proteins have been reported in HD as well34,35.

Genomic instability can also directly impact proteostasis. As described above, genomic
instability can lead to an accumulation of mutations. Mutations in protein coding regions
can alter amino acid sequences of the proteins they encode, which can lead to protein
misfolding or loss of function. Protein misfolding is the precursor to aggregation and
proteostasis disruption. In addition, a mutation in a gene that encodes an essential DDR
protein resulting in loss of function could lead to a positive feedback loop of accelerated
genome instability and proteostasis disruption.
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Telomere Attrition
Telomere attrition (shortening) can also lead to proteostasis collapse and vice versa.
Telomeres are long structures of nucleotide repeats located at the ends of linear
chromosomes that function to maintain chromosome stability. DNA replication for each
round of cell division causes telomere shortening due to limitations of DNA polymerase’s
ability to replicate the ends of chromosomes36. Some cells have telomerases that can
elongate the telomeres, but they are primarily only present in fetal tissue, germ cells, adult
stem cells, neural stem cells (NSC), and activated lymphocytes37–41. Therefore, with each
round of cell division in most non-stem cells, telomeres are shortened and have limited
capacity for regeneration. When telomere length becomes too short, cell cycle arrest
occurs leading to either cellular senescence42,43 or cell death through apoptotic44 or
autophagic45 cell death. In the case of fully differentiated neurons, which are post-mitotic,
telomere shortening also occurs with age due, in part, to oxidative stress and DNA
damage46,47. As discussed previously, protein aggregates present in NDs can cause
oxidative stress and DNA damage, which in turn, may lead to accelerated telomere
shortening. Additionally, a recent study showed that AD associated Aβ oligomers can bind
to, and inhibit the function of telomerases48. Telomerase expression in the human brain
is largely isolated to NSCs, which are largely localized to areas that experience high levels
of neurogenesis and remodeling such as the subventricular zone of the lateral ventricle
and the subgranular zone of the hippocampus (highly impacted in AD) 49,50.

In terms of telomere attrition itself causing proteostasis disruption, artificially shortened
telomers have been shown to lead to increased α-synuclein accumulation and
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aggregation in mice51 and a neuroblastoma cell line52. These results show that shortened
telomeres, which occur with age, may lead to increased protein accumulation and another
positive feedback loop that accelerates disease progression.

Epigenetics
Epigenetics refers to the phenotypic changes in an organism or individual cells that are
not caused by DNA sequence. It plays a crucial role during development by switching on
and off specific genes to allow for cellular differentiation into all the different cell types
present in multicellular organisms and can cause major phenotypic changes in the entire
organism. A striking example of this is demonstrated by the major phenotypic and
behavioral differences seen between queen and worker honeybees despite identical DNA
sequences53. Epigenetic changes are generally mediated by DNA methylation, histone
modifications including acetylation, methylation, and phosphorylation, and nucleosome
positioning54–56. Histones form complexes that provide structural support for
chromosomes by allowing DNA strands to wind around them in a coil-like manner. The
DNA wrapped histone complexes are called nucleosomes, and control access to DNA for
gene expression. In general, histone acetylation causes DNA strands to loosen from the
histone complex exposing genes in that region to molecular machinery needed for
expression, whereas methylation tightens the coil around the histone complex essentially
turning those genes off. DNA methylation also functions to decrease gene expression by
directly blocking transcription. Epigenetic changes happen all the time and are an
essential component of a healthy cell. However, some of these changes can lead to
deleterious consequences with age.
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In general, epigenetic control of gene expression becomes more relaxed with age leading
to the expression of unneeded proteins. For example, it has been observed in yeast that
replicative aging is accompanied by a global decrease in core histones57, which leads to
increased global transcription and elevated protein abundance in these aged cells due to
improperly exposed DNA regions58. In addition, elevating histone expression has been
shown to extend lifespan suggesting that decreased histone levels has a direct impact on
aging and cell health59. This age-related global histone decrease has also been observed
in aged nematodes60, human primary fibroblasts61, and in senescent human cells62
suggesting this may be common among eukaryotes. In addition, global hypomethylation
is also a common theme in epigenetic aging studies which also leads to increased global
transcription and elevated protein levels63. In the context of ND specifically, researchers
have reported hypomethylation in the promoter region of the amyloid precursor protein
(APP)64. They hypothesize that this leads to elevated amyloid-β levels and subsequent
aggregation seen in AD. As suggested by Ebstedt et al. in 201465, high protein abundance
and increased aggregation propensity are positively correlated. Therefore, this
underregulated global protein expression that occurs with age could crowd the cell with
unneeded proteins leading to increased aggregation propensity and overall proteostasis
disruption over time.
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Mitochondrial dysfunction

Figure 3. Schematic outlining the free radical theory of aging as it relates to mitochondrial function. Normal
mitochondrial function generates reactive oxygen species (ROS) over time which leads to oxidative damage.
Damage to mitochondrial DNA (mtDNA) can cause mitochondrial dysfunction which leads to accelerated ROS
production leading to a positive feedback loop.

Mitochondria are the main energy producing organelles present in eukaryotic cells. They
consist of a smooth outer membrane with a folded inner membrane which houses
sophisticated electron transport chains (ETC) that generate ATP through oxidative
phosphorylation. Mitochondria are also responsible for several other cellular processes
like cell death mediation, fatty acid oxidation, and iron sulfur cluster generation.
Mitochondrial dysfunction has historically been thought to be a major cause and even the
root cause of cellular aging. In 1956, Denham Harman proposed the “free radical” theory
of aging which proposes that organisms age due to the buildup of oxidative damage66
caused by reactive oxygen species (ROS) which are primarily generated by the
mitochondria. For decades, this theory dominated the aging field and still does to some
extent today. However, theories about the mitochondrial contribution to aging have
become more nuanced since then. Mitochondria are still thought to contribute significantly
to the buildup of cell damage, but it may do so by aggravating other aging hallmarks. In
fact, a recent review connects various components of mitochondrial dysfunction (oxidative
stress, metabolite intermediates, mitochondrial protein destabilization, mitochondrial DNA
damage, Decreased dynamics, mitophagy, and oxidative phosphorylation) to the 8
8

additional hallmarks of aging (Fig. 3)67. Although mitochondrial theories of aging have
diversified, the following section will discuss the oxidative damage component since it is
heavily implicated in proteostasis health.

In the process of ATP production, the ETC generates copious quantities of ROS, which
are highly unstable oxygen containing free radicals that react readily with many other
molecules in the cell. At low concentrations, ROSs are useful and even required for
various chemical reactions to occur in a healthy cell. However, overproduction and
accumulation of ROS can lead to significant cellular damage known as oxidative stress
by destabilizing both proteins68 and DNA69. Oxidative stress can impact proteostasis by
causing protein aggregation in several ways including protein and DNA carbonylation and
disrupting protein degradation23. Oxidative stress induced protein carbonylation is the
irreversible addition of a carbonyl group (CO) which has been shown to cause protein
aggregation and crosslinking when carbonylation is excessive70,71. The precise
mechanism mediating this increased aggregation propensity is unclear, but based on
studies focused on the related dicarbonyl species methylglyoxal (MGO) and glyoxal (GO),
carbonylation likely disrupts the secondary and tertiary structure of proteins leading to
destabilization and susceptibility to aggregation72. As mentioned previously, aggregated
proteins themselves can also disrupt mitochondrial function24–28. More specifically, αsynuclein has been shown to directly interact with the ATP synthase of the ETC leading
to disruption of membrane permiability24. This can lead to elevated ROS production and
oxidative stress resulting in a vicious cycle of protein destabilization and mitochondrial
disruption.
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Several studies have shown that mitochondrial production of ROS increases with age73–
78

, and as such, oxidative damage also increases with age79–84. In addition, several

comparative studies have shown that ROS production is negatively correlated with
longevity in several species85–89. However, others suggest oxidative stress is not always
deleterious. In fact, the naked mole rat—the longest-lived rodent species—is
characterized by extensively elevated oxidative damage compared to age-matched
control mice suggesting a possible protective or compensatory mechanism at play90,91. It
is now understood that slightly increased ROS production caused by mitochondrial
disruption can be beneficial for several organisms.

Mildly increasing ROS levels in several varied species either pharmacologically or
genetically has been shown to extend lifespan. For example, treatment with chemicals
that cause mildly elevated mitochondrial ROS production at low concentrations (i.e.
rotenone, metformin, paraquat, and juglone) extend lifespan in yeast92, nematodes93–100,
and mice100, and treatment with antioxidants that neutralize ROS (i.e. NAC, Vitamin C or
Vitamin E) can reverse this phenotype97. In C. elegans, genetically removing superoxide
dismutase, SOD-2 – which is responsible for neutralizing excess ROS produced by the
mitochondria, results in elevated ROS and extended lifespan101. In general, mutations
that disrupt the mitochondrial ETC and cause extended lifespan in C. elegans are
collectively referred to as Mit (Mitochondrial) mutants102. Several Mit mutants have been
described including clk-1, nuo-6, and isp-1, and they all have been shown to increase
lifespan even with increased ROS levels95,103,104. Several mechanisms proposed to
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contribute to this phenomenon are outlined in a recent review105, but one of the primary
processes upregulated and necessary for life extension in Mit mutants is the
mitochondrial unfolded protein response (UPRMT)106. The UPRMT is akin to the
endoplasmic reticulum mediated UPR in that it results in upregulation of various stress
response proteins (i.e. chaperones), but is exclusively activated in response to
mitochondrial stress107 such as ETC impairment108, accumulation of unfolded proteins
within mitochondria109, mitochondrial DNA damage, inhibition of mitochondrial
chaperones or proteases, and increased ROS levels110,111. The purpose of UPRMT is to
maintain mitochondrial proteostasis, but its upregulation in Mit mutants is thought to
provide additional benefits that increase global proteostasis and resistance to various
stressors.

In addition to chaperone upregulation, enhanced protein degradation may also play a key
role in Mit mutant life extension. Studies have shown that autophagy is upregulated in
multiple Mit mutants, and removing genes necessary for autophagy upregulation reverses
the observed life extension112,113. The proteasome has also been implicated in Mit mutant
longevity. It was found the knocking down jun-1, which targets several age related and
ubiquitin dependent protein catabolism genes, in a long lived Mit mutant completely
extinguished life extension114. Knocking down dnj-21 causes mild mitochondria stress by
disrupting mitochondrial protein import in C. elegans and leads to increased lifespan115.
In these animals, researchers observed stimulated degradation of ubiquitinated
substrates in vivo and found that proteasome inhibition in these animals led to
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accumulation of oxidatively damaged proteins and decreased lifespan115. This suggests
increased proteasome activity may directly contribute to longevity in this knockdown.

The benefits of partial mitochondrial inhibition are so robust across species that it has
been proposed as a potential treatment for AD (Fig. 4)116. To this point, a recent 2021
study reported that partial inhibition of the ETC complex I in APP/PS1 (AD model) mice
ameliorated AD pathology and cognitive deficits by improving energy homeostasis,
neuronal health, and proteostasis, while reducing oxidative stress and inflammation in the
brain117. Several compounds that inhibit complex 1 of the ETC including metformin,
resveratrol, berberine, and epigallocatechin-3-gallate have been or are currently being
clinically investigated for various NDs116, but even more are in clinical trials for metabolic
disorders like type 2 diabetes myelitis and obesity. It is also important to note that only
mitochondrial ROS upregulation extends lifespan as cytosolic ROS upregulation does not
yield the same benefits103. It is possible that the oxidative stress component of the free
radical theory of aging holds true when oxidative stress related to nutrition is considered.

Figure 4. Schematic showing potential benefits of inhibiting complex I of the ETC. Mild stress via partial
inhibition of the ETC’s complex I could induce and integrated stress response that leads to
neuroprotection and extend healthspan/lifespan. doi:10.1016/j.apsb.2021.11.003
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Deregulated nutrient sensing
To maintain stable systemic nutrient levels in the face of intermittent food intake,
multicellular organisms have evolved sophisticated mechanisms to store nutrients after
feeding for later use. Nutrient sensing refers to the cell’s ability to detect and respond to
the presence or absence of various fuel substrates such as AAs, carbohydrates(glucose),
and lipids. The major nutrient sensing pathways in eukaryotes include insulin/insulin-like
growth factor signaling (IIS) and AMP activated kinase (AMPK) signaling. Both pathways
control cellular activities through the mechanistic target of rapamycin (mTOR) signaling
pathway. IIS is active during the “fed” state where nutrients are abundant, and its activity
stimulates mTOR signaling. AMPK signaling is activated during nutrient deprivation and
exercise where elevated levels of AMP are present, and its activation suppresses mTOR
signaling. mTOR controls several metabolic processes that can profoundly impact
proteostasis by altering protein production and degradation (Fig. 5)118.

When activated, mTOR stimulates several energetically expensive growth-related
processes including lipid and nucleotide biosynthesis, glucose metabolism, and protein
synthesis while inhibiting catabolic pathways such as autophagy119. If left unchecked,
mTOR’s simultaneous activation of protein synthesis and inhibition of protein degradation
can cause the accumulation of proteins, many of which could be damaged or misfolded.
To this point, knocking out Pten, one of the proteins needed to inhibit mTOR signaling in
mice, causes constitutive mTOR activation and subsequent accumulation of both
amyloid-β & α-synuclein in ND mice120.
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Figure 5. Activated mTORC1
regulates
several
metabolic
processes. Downstream, mTORC1
signaling inhibits autophagy and
stimulates mRNA translation for
increased
protein
production,
glycolysis, lipid synthesis for making
membranes, pentose phosphate
pathway and de novo pyrimidine
synthesis which promotes ATP
production, NADPH, and major
macromolecules required for cell
growth. doi:10.1038/ncb2763

Overactive mTOR signaling due to unrestricted food intake can also lead to obesity and
insulin resistance, i.e., Type 2 Diabetes Myelitis (T2DM). A common theme observed in
sporadic AD (SAD) is decreased insulin and insulin receptors (IRs) in the brain121 and
insulin resistance has been observed in AD brain tissue122,123. These observations have
led researchers to designate SAD as “type 3 diabetes”124. T2DM is considered a
significant risk factor for developing AD. In addition, a study examining the relationships
between diabetes and AD showed that 81% of AD patients examined had either T2DM
(35%) or glucose intolerance (46%)125. The relationship between these two conditions is
positively correlated, but a causal relationship is unclear. A brain specific insulin receptor
knockout in mice caused no impact on brain development or neuron health and survival;
however, these mice did go on to develop diet sensitive obesity and insulin resistance126.
This suggests that while brain specific insulin interactions are needed to regulate food
intake, they do not appear to be directly implicated in AD pathology. It has been
hypothesized that chronically elevated systemic glucose may be a driving force in the
T2DM/AD relationship.
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In the case of T2DM, decreased cellular glucose uptake due to impaired insulin signaling
can result in hyperglycemia. Chronic hyperglycemia related to diabetes or even just high
sugar diets and can lead to increased glycosylation of DNA, lipids, and proteins which,
through a series of reducing reactions, become advanced glycation end products
(AGEs)127,128. AGEs are produced naturally and are usually removed but can accumulate
over time with chronic hyperglycemia129. This diverse group of irreversibly modified
molecules are is thought to contribute to many age related conditions like arterial
stiffening and diabetic complications by causing inflammation and oxidative stress
(reviewed here130), but has also been specifically linked to proteostasis disruption and
NDs131. For example, protein deposits from human AD brains had three times higher AGE
content compared to age matched controls132. In addition to being detected in areas
surrounding Lewy bodies in PD patients133, AGEs have also been found in newly formed
Lewy bodies in pre-PD patients suggesting AGEs may play a role in initiating aggregate
formation in PD134. To this point, in vitro studies show AGEs directly cause α-synuclein
crosslinking135, and studies using neuroblastoma and mouse AD models suggest
glycation of tau and amyloid-β also leads to crosslinking and drives the formation of stable
oligomers136,137. In addition, AGE formation has been shown to stimulate amyloid
precursor protein (APP) expression, which leads to higher levels of Aβ peptides that can
propagate aggregation138. Taken together, deregulated nutrient sensing and poor diet
that results in excess AGE production from chronic hyperglycemia may directly contribute
to proteostasis collapse. Deregulated nutrient sensing can be prevented in many cases
through proper diet and exercise though. In fact, nutrient sensing pathways can be
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harnessed to extend lifespan and prevent the development of age-related diseases
through dietary restriction or treatment with compounds that can alter these pathways.

Dietary restriction (DR) has been shown to decrease aging phenotypes and extend
lifespans of several model organisms ranging from yeast to humans139–141. DR decreases
IIS signaling and stimulates AMPK, which suppresses mTOR and activates catabolic
processes like autophagy142. However, AMPK appears to become less responsive with
age suggesting that a potential mechanism behind age-related protein accumulation is
the inability to inhibit mTOR signaling143–146, but this can be bypassed through
pharmacological interventions. Rapamycin is a compound that stimulates autophagic
protein degradation by potently inhibiting mTOR and as such, has garnered great interest
in the field of aging147. Rapamycin treatment has been shown to extend the lifespans of
several different species including yeast148, flies149, nematodes150, and mice151. This
seemingly miracle drug has been FDA approved for decades as an antirejection
immunosuppressant for transplant patients, and many have argued that rapamycin also
be approved as an antiaging drug. However concerns about side effects have stalled its
FDA approval for this purpose152.

In addition to inhibiting mTOR signaling, AMPK activation upregulates the daf-16/FOXO
transcription factor, which has been the primary focus of C. elegans aging research since
the discovery of daf-2 mutants. A groundbreaking discovery was made in the early 1990’s
when researchers studying aging in C. elegans removed a gene (daf-2) that doubled the
lifespan in these nematodes153. Daf-2 was later determined to be the sole insulin receptor
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encoded in C. elegans and is homologous to both the insulin and IGF-1 receptors in
mammals. This discovery solidified C. elegans as a major animal model used in aging
research around the globe, and vast efforts have been put forth to determine the
mechanisms responsible for life extension in daf-2 mutants. It was determined that the
life extending effects of daf-2 mutants and another long-lived mutant downstream of daf2, (age-1/PI3K), are highly dependent on the transcription factor, daf-16 (FOXO
homolog)154 which drives the expression of genes involved in metabolism, cellular stress,
and antimicrobial response155–158. In WT, daf-2 negatively regulates daf-16; therefore,
removing daf-2 results in the constitutive activation of daf-16 and expression of
downstream components under its transcriptional control. At the protein level, daf-2
mutants contain higher levels of several stress response proteins including proteasome
subunits, molecular chaperones159–161, and autophagy elements162,163—similar to Mit
mutants discussed previously. As such, it is thought that increased proteostasis
contributes to lifespan extension in these mutants. Taken together, nutrient sensing and
energy metabolism are clearly vitally important in maintaining cellular health and can
directly impact proteostasis by modulating vital components of the proteostasis network.
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Proteostasis Network
Protein homeostasis (proteostasis) is achieved through a vast network of quality control
proteins that maintain protein solubility and functionality by regulating protein
biosynthesis, stability, and degradation164. Collectively, these protein quality control
components are referred to as the proteostasis network (PN)(Fig. 6)165. The goal of the
PN is to prevent protein aggregation and to maintain optimal protein concentrations. The
first level of regulation starts at the ribosome where mRNA is translated into protein. If a
ribosome detects faulty mRNA
during translation, it halts protein
translation

and

disassociates

from the RNA strand which is
subsequently

degraded166.

In

the event of global proteostasis
disruption, the cell responds
Figure 6. The proteostasis network (PN). The PN includes three
modules: protein synthesis, folding, and degradation. The three
modules are tightly connected to one another, and all
components work together to maintain the correct protein
homeostasis.
ALP: autophagy-lysosome pathway. UPS:
ubiquitin-proteasome system. doi:10.3390/ijms21176405

through

various

signaling

pathways to suppress protein
synthesis while at the same time

selectively stimulating translation of stress response proteins (i.e., chaperones).
Decreasing global translation lowers the amount of newly synthesized proteins in the cell
which frees up chaperones to help refold stress induced non-native/aggregate-prone
proteins167,168. Chaperones are essential for cell survival and recovery from conditions of
stress. Their removal or loss of function leaves the biological system susceptible to
proteotoxic insult, and as such, many human diseases associated with chaperone
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mutations have been described169. On the other hand, experimental overexpression of
multiple types of chaperones have been shown to increase lifespan by reducing protein
misfolding and subsequent aggregation170–172.

Chaperones
As the central dogma of molecular biology states, DNA is transcribed into mRNA which
is then translated to a protein with a unique polypeptide chain (Amino Acid [AA]
sequence). The unique sequence of AAs in the polypeptide chain generally determines
how a protein should fold to function correctly. Small cytosolic proteins can spontaneously
fold

into

the

correct

structure

through

hydrophobic

collapse

where hydrophobic AA
residues
sequestered
Figure 7. Two types of free energy landscapes in protein folding. A.
Smooth energy landscape that provides an unobstructed path for the
protein to fold into its native state. B. Rugged energy landscape that is
more characteristic of most large multidomain proteins in eukaryotes
showing peaks and valleys where proteins can become trapped in a
nonfunctional or even toxic conformation. N denotes the native state.
doi:10.1038/nsb0197-10

become
inside

a

globular structure away
from

the

hydrophilic

cytosol. This can be
conceptualized as the

protein funneling down a smooth free energy landscape to reach its native state(Fig.
7A)173. Because the energy landscape is smooth, the polypeptide chain can easily flow
down to its native state. However, most of the time, especially for larger multisubunit
proteins in eukaryotes, the energy landscape is rugged with many peaks and valleys
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along the way to its native state where it can become trapped in a non-native misfolded
state (Fig. 7B)173. For this reason, assistance from molecular chaperones is needed to
ensure proper folding of large newly synthesized proteins. Additionally, mature proteins
can become misfolded and prone to aggregation due to a variety of environmental factors
and usually require the assistance of chaperones to refold correctly or target them for
degradation. The existence of molecular chaperones were first discovered in 1974 when
researchers from the California Institute of Technology discovered that D. melanogaster
exposed to high temperatures caused chromosomal “puffing” and expression of highly
conserved proteins which were later dubbed “heat shock proteins” (HSPs)174,175. Since
then, several chaperone families have been described and are generally categorized by
their molecular weight (Hsp100, Hsp90, Hsp70, Hsp60, Hsp-40, and small HSPs [sHSPs;
<40kDa]) (Table 1)176.

Hsp70. Hsp70s (or DNA-K in prokaryotes) are the primary family of chaperones that help
to fold newly synthesized proteins and function in an ATP dependent manner. In
conjunction with the nascent polypeptide-associated complex (NAC) and Hsp40, Hsp70
assists folding in a co-translational manner177. NAC senses the nascent polypeptide
regions as they emerge from the ribosome during translation178 and passes them off to a
series of Hsp70 chaperones which bind to hydrophobic regions like clamps on a rope to
hold the polypeptide chain in a linear unfolded state179. This is especially important for
larger multi-domain containing proteins because it limits non-native contacts between
domains. Once a domain is fully translated, Hsp40 induces Hsp70 to hydrolyze ATP and
release the polypeptide which then collapses into its native structure. If correct folding is
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not achieved in this step, the process is either repeated or the partially folded proteins are
passed to Hsp90 or Hsp60 to complete the folding process. Hsp70 overexpression has
been shown to extend the lifespan of C. elegans alluding to its importance in proteostasis
health and longevity170

Hsp60. The Hsp60 family, broadly known as chaperonins, are multi-subunit barrel like
structures with an internal chamber that provides an optimal environment for individual
proteins to refold properly. Due to divergent evolution, two distinct forms of chaperonins
exist (GroEL in prokaryotes & TRiC in eukaryotes). Group I, the GroE chaperonin system
in prokaryotes, consists of two stacked heptameric rings that form the folding
compartment (GroEL) and a separate 7-subunit lid (GroES) that traps substrates within
the chamber180–182. In the absence of ATP and the GroES lid, the inner surface of the
GroEL chamber is hydrophobic which allows for binding to misfolded proteins that have
exposed hydrophobic regions due to improper folding181–184. After the misfolded substrate
is sequestered within the chamber, GroES binds to and closes the entry pore of GroEL in
an ATP dependent manner. GroES binding causes major structural changes to occur
within the GroEL chamber leading to a hydrophilic and negatively charged environment
which encourages the trapped substrate to refold correctly185. The correctly folded protein
is then released following ATP hydrolysis and GroES dissociation. If the targeted protein
remains incorrectly folded, this process is repeated until proper folding is achieved. The
group II chaperonin, TRiC, exists cytosolically in eukaryotic cells and functions similarly
to GroEL, but the rings consist of 8 subunits as opposed to 7, and instead of a separate
lid, TRiC subunits have finger-like extensions that act as a built-in lid186.
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Table 1. Summary of the structure and function of each heat shock protein
doi:10.1093/embo-reports/kve253.family.

Chaperone
Hsp70

Structure/Mechanism

Function
Nascent protein folding: ATP dependent
stabilization of hydrophobic regions to
prevent aggregation a facilitate folding

Hsp60: GroEL-GroES

ATP dependent facilitation of protein
folding to native state

Hsp90

ATP dependent conformational
maturation of steroid hormone receptors
and signal transducing kinases

Hsp100: ClpA-ClpP

ATP-dependent disaggregation,
unfolding, and degradation

sHsps

ATP-independent stabilization of
unfolded proteins during proteotoxic
stress

HSP90. Hsp90 is one of the most highly expressed chaperones in all eukaryotic cells
under normal conditions because it performs essential functions in unstressed cells. It
interacts with a wide variety of different substrates or “clients” and seems to primarily
focus on metastable proteins that are “regulatory hubs” for biological networks including
protein kinases and steroid hormone receptors187,188. Hsp90 exists as a dimer, and each
monomer has three functional domains including an N-terminal domain (NTD), middle
domain (MD), and C-terminal domain (CTD)189–191. The NTD is responsible for ATP
binding and hydrolysis, while the CTD mediates ATP-dependent dimerization. The MD
contains a hydrophobic region that recognizes mediates the maturation of partially folded
22

proteins into their native conformations. While Hsp90 successfully mediates the
maturation of most of its client proteins, it has paradoxically been shown to facilitate the
aggregation of the microtubule associated protein tau which is heavily implicated in
several NDs192. It is thought that Hsp90 binding to tau leads to a conformational chain
that promotes oligomerization193,194. Hsp90 inhibition has been shown to decrease tau
accumulation in transgenic ND mice195 so this treatment has generated some interest
recently196. However, functional Hsp90 has been shown to be required for proper
assembly and maintenance of the 26S proteasome so its inhibition may not be a clinically
viable treatment for protein aggregation diseases in general197,198. It may be a more
suitable treatment for certain types of cancer where Hsp90 has been shown to be
upregulated199.

Hsp100. The Hsp100 family are hexameric AAA-ATPases that function as disaggregases
by mechanically unfolding aggregated proteins through a central pore for subsequent
degradation or to give them a chance to refold. In many ways Hsp100 chaperones are
structurally and mechanistically similar to proteasomal ATPases, but what separates true
Hsp100s from proteasomal AAA-ATPases is their ability to break down aggregates. The
most widely studied and well understood chaperones in the Hsp100 family are Hsp104 in
S. cerevisiae and ClpB in E. coli. Homologs are found in eubacteria and eukaryotes with
the exception of animals, and, as such, animals have a comparatively limited capacity to
disassemble aggregates200–202. Hsp104 is a 102KDa homohexameric AAA-ATPase in S.
cerevisiae first reported by Sanchez and Lindquist in 1990 and was found to be required
for heat resistance (50˚C) following a mild pre-heat treatment (37˚C)203. It was later found
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that large dense aggregates formed after heat shock were able to be resolubilized by
Hsp104204. This was a groundbreaking discovery at the time because proteins were
largely considered unsalvageable once sequestered into insoluble aggregates. After
disaggregation by Hsp104, some proteins can refold spontaneously, but the large majority
require the assistance of Hsp70205. This was found to be true for the homologous ClpB in
E. coli and T. Thermophilus as well206–208. Hsp104 variants have been shown to suppress
aggregates of human ND proteins, α-synuclein, TDP-43, and FUS, and ameliorate their
toxicity when introduced to yeast and nematodes209. Hsp104’s ability to disassemble ND
aggregates continues to garner interest from researchers looking to develop a way to
disassemble aggregates present in human disease.

Small heat shock proteins (sHSPs). sHSPs are arguably some of the most important
yet underappreciated components of the PN. However, their vital role in maintaining
protein solubility has garnered increasing attention in recent years210. The sHSP family is
a ubiquitous family of chaperones that generally have a molecular mass of less than
40KDa (majority are around 20KDa in size) and act as first responders under conditions
of stress to prevent irreversible protein aggregation211. They are upregulated early in
response to global protein misfolding events, and unlike the chaperones mentioned thus
far, they are ATP independent. A common feature of all sHSPs is the presence of a core
α-crystallin domain between variable N and C-terminal domains 212. α-Crystallins are well
known in higher order eukaryotes as the protein responsible for maintaining protein
solubility in eye lenses that allows for the unhindered passage of light. Crystallins make
up ~90% of the protein found in eye lenses which highlights the capacity of sHSPs to
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mediate and maintain protein solubility213. Several other sHSPs exist in humans and other
eukaryotes with potentially unique mechanisms that are not entirely understood. In
general, monomeric sHSPs typically assemble into higher order oligomeric structures
containing between 12 to over 40 subunits under normal conditions, though they can also
exist as dimers214. When a stress such as heat or oxidation occurs, sHSPs levels are
rapidly increased and triggers the large oligomer complexes to shift to smaller
complexes215–219. A conformational shift occurs with individual subunits resulting in
exposure of substrate binding sites that bind to unnaturally exposed hydrophobic regions
of misfolded or partially misfolded proteins215,220,221. They then hold these proteins until
the more complex ATP-dependent chaperones discussed previously are free to assist in
refolding217,220. In addition to combating sudden proteotoxic stress, sHSPs appear to play
a key role in lifespan extension as well. For example, Hsp-16, a sHSP in C. elegans, has
been shown to be upregulated in multiple long-lived mutants including daf-2 and age1155,158,222 and its transgenic overexpression can increase lifespan in both C. elegans and
D. melanogaster170,171,223,224.

Overview
Thus far, this review has discussed the relationship between proteostasis and the
hallmarks of aging and how molecular chaperones contribute to protein quality control.
Next, the final component of the proteostasis network, protein degradation, will be
discussed. When a protein is no longer needed or damaged beyond repair, it is targeted
for degradation. Protein degradation is performed by either the ubiquitin proteasome
system (UPS) or the lysosome (Autophagy). The UPS oversees the targeted degradation
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of individual damaged or misfolded proteins and is responsible for the 90% of all protein
degradation while the lysosome degrades larger objects such as insoluble protein
aggregates and entire organelles225.

Protein Degradation: Proteasome
Non-lysosomal ATP dependent protein degradation was first described in 1977 by
Etlinger and Goldberg when researching protein degradation in reticulocytes, which lack
lysosomes when fully mature226. Prior to this discovery, it was widely believed that most
proteins were long lived, and that degradation was performed primarily by the lysosome.
In 1978, shortly after the discovery of this unique degradation system, Ciechanover et al.
found that degradation of denatured globin from reticulocyte lysates was dependent on
being conjugated to unique chains of proteins which they termed ATP-dependent
proteolysis factor 1 (APF-1)227. Two years later in 1980, Wilkinson et al. determined that
APF-1 is actually ubiquitin228, which was discovered the year before APF-1 in an
unrelated study and aptly named ubiquitin because of its apparent ubiquitous
expression229. Shortly thereafter, a multiprotein protease complex was isolated by Wilk
and Orlowski and dubbed the multi-catalytic proteinase complex230. However, it wasn’t
until 1987 and 1988 that the proteolytic complex responsible for ubiquitin dependent
degradation was discovered and defined as the 26S proteasome231,232. It consists of a
19S regulatory particle and a 20S proteolytic “core” particle. Although many discoveries
have been made regarding the ubiquitin cascade, this review will focus primarily on the
20S and 26S proteasomes themselves.
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Figure 8. Schematic of the 26S proteasome. The 26S proteasome consists of the 19S regulatory
particle (consisting of a lid and base) bound to one or both ends of a hollow barrel shaped 20S
proteasome. The 19S consists of a lid (purple) and base (green) region for ubiquitin binding and protein
unfolding respectively. The 20S consists of two β-rings (blue) which house the proteolytic sites in
between two α-rings (red) which contain the gating residues. doi:10.1038/nrm2630

The 20S proteasome is the proteolytic component of the UPS. It is a barrel like structure
that has four stacked heptameric rings (⍺7, β7, β7, ⍺7)(Fig. 8)233. Within the 20S chamber
exists three pairs of distinct active sites on the β-subunits that cleave at specific areas of
proteins based on chemical identity: hydrophobic (chymotrypsin-like; β5), Basic (trypsinlike; β2), and Acidic (caspase-like; β1). The α-rings’ N-termini form “gates” that deter nonspecific degradation by interacting with one another to form a folded structure over the
central pore preventing unregulated substrate entry234. The gate’s structural stability is
mediated by the evolutionarily conserved YDR motif (Tyr-Asp-Arg[Ser]), which stabilizes
both the closed and open states of the 20S substrate gate234–238. Several different
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regulatory caps that bind to the 20S proteasome exist in the cell to aid in regulating protein
degradation by the proteasome (i.e., PA200/Blm10, PA28αβ, PA28γ, 19S), and many of
these caps have been extensively characterized239–243. The 19S regulatory particle (RP)
is one of the primary regulatory caps in the cytosol and is responsible for ubiquitin
dependent degradation. It binds to one or both ends of the 20S proteasome creating the
26S (RP1-20S or RP2-20S) proteasome. The RP can be divided into two functional
regions – lid & base. The base consists of a hexameric ring of AAA+ ATPases that mediate
protein unfolding, and the lid contains ubiquitin receptors and deubiquitinases for
targeting substrates for degradation244–247. The C-termini of the ATPase subunits contain
a HbYX (hydrophobic, tyrosine, most amino acids) motif, which docks into intersubunit
pockets in the 20S complex causing conformational changes in the 20S α-subunits and
triggers gate-opening248. Other regulators modulate activity in a distinct mechanism.

As described above, many age-related diseases, including virtually all neurodegenerative
diseases, can be characterized by protein misfolding and accumulation6,249,250. The
reason for this proteostasis collapse is clearly multifaceted, but in many cases, these
diseases have also been shown to have decreased UPS function which likely contributes
to protein accumulation225,251–257. To this point, synthetic proteasome impairment in mice
and rats alone has been shown to cause pathologies and symptoms associated with
neurodegenerative diseases258–262. The definitive cause of decreased proteasome
function with age is not entirely understood. However, many previous studies have
reported that one cause of proteasomal inhibition in aging and disease states could be
the presence of oligomeric ND associated proteins and other types of protein
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aggregates254,263–267. Identifying the mechanism behind proteasome inhibition by toxic
oligomers will be the focus of Study 1 in this Dissertation.

Proteasome Activation
Considering the evidence of decreased proteasome function in aging and disease, a great
deal of effort has been put forth to discover ways to stimulate its activity. Many unique
approaches have been used to elicit proteasome activation including modifications to the
26S, genetic manipulations, and small molecule 20S activation.

Usp14. Increased 26S activity has been achieved through a variety of approaches either
targeting the 26S itself or its interacting proteins. For example, ubiquitin specific protease
14 (Usp-14) and its yeast homolog, Ubp6, is a proteasome associated deubiquitinase
(DUb) that has been shown to modulate 26S activity. Usp14/Ubp6 protects proteins from
degradation by removing ubiquitin chains from proteasome-bound substrates as well as
allosterically inhibiting the 26S268, but it has also been shown to mediate proteasome
activation under specific circumstances. In 2009, a study showed that ubiquitin conjugate
binding to Usp14/Ubp6 caused proteasomal activation by allosterically opening the
gate269. Further experimentation showed that binding of a transient state inhibitor,
ubiquitin aldehyde, caused activation as well indicating that proteasomal activation is, at
least in part, independent of Usp14’s catalytic activity270. This activation was found to be
mediated through Usp14’s ubiquitin-like (UBL) domain, and as such, several other UBL
domain containing proteins have been shown to stimulate 26S activity as well271. In
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addition, UBL domain overexpression in HELA cells resulted in a 60% increase in
degradation of endogenous proteins suggesting potential therapeutic applications271.

26S Phosphorylation. Post-translational modifications (PTMs) of the 26S are key
regulators of the proteasome complex and have been reported to alter its localization,
structure, and activity. PTMs that alter activity have garnered a great deal of interest in
recent years amid efforts to increase proteostasis in aging and disease. It was discovered
in 2004 that 26S proteasomes in the liver of ethanol-fed rats are hyperphosphorylated
and had decreased activity compared to controls272. Two years later, in 2006, Zong et al.
found that the phosphorylation pattern of proteasomes in mouse cardiac tissue conferred
increased peptidase activity and that this phosphorylation pattern was mediated by
protein kinase A (PKA)273. Furthermore, treatment with forskolin, which increases
amounts the PKA second messenger cyclic-AMP (cAMP), simulates 26S proteasome
activity in rat spinal cord neurons and reduces accumulation of ubiquitinated proteins274.
Similarly, rolipram, which increases cAMP levels through phosphodiesterase 4 inhibition,
has been shown to increase proteasome activity in zebrafish and mice267,275. Several
other protein kinases including PKG276, CAMKIIα277, and DYRK2278 have also been
shown to phosphorylate specific 26S subunits leading to its activation. The ability to
stimulate proteasome activity through phosphorylation is significant because kinases can
be activated by a wide range of stimuli. As such, various hormones and physiological
states that increase levels of cAMP have also been shown to stimulate proteasome
activity279. However, kinases have a broad range of targets, so targeting specific kinases
may result in unwanted side effects.
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20S activation
Many studies focus on the importance of the 26S proteasome because it is responsible
for the ubiquitin dependent protein degradation, which is a vital component indeed, but
tend to underappreciate the contribution of free (uncapped) 20S proteasomes until recent
years280. In fact, quantitative proteomics have recently shown that an average of 64% of
the proteasome populations from multiple cell lines are free 20S281,282, and biochemical
analyses found that the 20S is responsible for degrading more than 20% of all cellular
proteins283. A recent 2021 study showed evidence that the 20S may be able to degrade
ubiquitinated proteins284, but most of its degrative activity is thought to be ubiquitin
independent. The major substrates of the 20S are largely characterized as intrinsically
disordered proteins (IDPs) and proteins with intrinsically disordered regions (IDRs) which
together make up ~40% of all cellular proteins285. IDPs and IDRs are unstructured under
physiologic conditions due to their low proportion of hydrophobic AAs and high
proportions of charged/hydrophilic AAs286. Most of the proteins implicated in NDs are
considered IDPs so activating 20S mediated degradation may be a viable and even
preferred approach to degrading ND associated proteins.

β5 overexpression. Some studies have sought to increase overall proteasome mediated
degradation through 20S subunit overexpression. Overexpression of the 20S’s β5 subunit
increases chymotrypsin-like (CTL) activity in mammalian cells, C. elegans, and D.
melanogaster, but the mechanism underpinning this increase remains unclear. In HELA,
WI38 (human lung) cells, and HL60 (human leukemia) cells, β5 overexpression leads to
upregulation of α1 and increased CTL activity, but the expression levels of other

31

proteasomal subunits was not definitively determined287. Studies in C. elegans and
human lens epithelial cells found β5 overexpression led to an overall increase in 20S
proteasome content and assembly, which they conclude is at least partially responsible
for the increased activity observed288,289. However, a more recent study in D.
melanogaster found that β5 upregulation caused increased CTL activity but did not lead
to an increase in proteasome levels suggesting the activation is mediated through a
different mechanism290. Nonetheless, in all cases, overexpression of β5 caused
increased CTL activity, and this increase in 20S activity led to increased lifespan and
resistance to oxidative stress. These results provide proof of concept that increasing 20S
activity is protective.

N-terminal Truncation. Other approaches involved intrinsic activation of the 20S itself
by targeting the proteasomal gate. As described above, the seven α-subunits of the
eukaryotic 20S contain N-terminal regions that fold over the central pore and serve as a
level of regulation to prevent unwanted substrate entry. The N-terminus of each alpha
subunit, while highly conserved, differs slightly in sequence, length, and structure and
therefore plays a unique role in regulating gate closure. The N-terminus of α3 is uniquely
important for gating in that it extends across the length of the entry pore acting as an
anchor by providing hydrogen bonding between the other α-subunit N-termini resulting in
a stable closed gate conformation237. A study in yeast found that an eleven-residue
truncation of the ⍺3’s N-terminus creates a 20S with a constitutively open proteasomal
gate and dramatically increased 20S peptide hydrolysis for all three active sites234. More
recently, it was shown that the expression of this proteasome construct in the mammalian
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HEK293 cell-line leads to resistance to proteotoxic stress induced by tau
overexpression291. It is important to note that this truncation of α3 in HEK293 cells was
exogenously overexpressed on a wild type α3 subunit background291. It was reported that
the modified α3 incorporated into the 20S proteasome well, but there still may be a small
population of WT proteasomes present. To our knowledge, no animal model has ever
been made with a similar gate-opening mutation. Creating this mutant in a multicellular
organism poses many potential issues because regulated protein degradation by the
proteasome is imperative for almost every cellular process including immune response,
signal transduction, development, metabolism, and progression through the cell cycle292–
294

. To this point, Bajorek et. al. showed that expression of this open-gate proteasome in

yeast hindered exit from stationary phase reducing population growth following nutrient
deprivation. However, in the logarithmic phase, population growth and cell division
remained normal295. Study two in this dissertation provides evidence that open-gate
proteasome expression in C. elegans is not only feasible but also beneficial as it extends
lifespan and protects against proteotoxic stress.
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ABSTRACT
Protein accumulation and aggregation with a concomitant loss of proteostasis often
contribute to neurodegenerative diseases, and the ubiquitin–proteasome system plays a
major role in protein degradation and proteostasis. Here, we show that three different
proteins from Alzheimer’s, Parkinson’s, and Huntington’s disease that misfold and
oligomerize into a shared three-dimensional structure potently impair the proteasome.
This study indicates that the shared conformation allows these oligomers to bind and
inhibit the proteasome with low nanomolar affinity, impairing ubiquitin-dependent and
ubiquitin-independent proteasome function in brain lysates. Detailed mechanistic analysis
demonstrates that these oligomers inhibit the 20S proteasome through allosteric
impairment of the substrate gate in the 20S core particle, preventing the 19S regulatory
particle from injecting substrates into the degradation chamber. These results provide a
novel molecular model for oligomer-driven impairment of proteasome function that is
relevant to a variety of neurodegenerative diseases, irrespective of the specific misfolded
protein that is involved.
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INTRODUCTION
The most common neurodegenerative diseases are characterized by an accumulation of
aggregation-prone proteins concomitant with a loss of proteostasis, which results in
progressive death of neurons

1–3

. Culminating evidence from the past two decades has

revealed that soluble, oligomeric forms of protein aggregates (such as Aβ in Alzheimer’s
disease, α-Synuclein (α-Syn) in Parkinson’s disease, and mutant huntingtin in
Huntington’s disease) are likely the most toxic species

4,5

. While different regions of the

brain are affected in these distinct diseases, proteotoxicity is a shared feature found in
these affected regions of the brain. This suggests that a common mechanism of
proteotoxicity could contribute to the development and progression of these distinct
neurodegenerative diseases.

Proteostasis
proteasome

6,7

is maintained by several systems in the cell including the ubiquitin–

system

(UPS),

chaperones,

chaperone-mediated

autophagy,

and

macroautophagy8. The UPS is the principal route for the degradation of intracellular
misfolded, damaged, or unneeded proteins9. If the efficiency of proteostasis systems
declines, misfolded proteins accumulate and aggregate in the cell, which can disrupt
normal cellular functions and even cause cell death10. Maintaining proteostasis is
especially important for neurons due to their complex architecture, long lifespan, and
inability to dilute aggregate load by cell division11. Most importantly, the UPS is critical for
normal functioning of neuronal synapses, including synaptic protein turnover, plasticity,
and long-term memory formation, which rely on tightly controlled changes in the
proteome11–15. Recently, Ramachandran and Margolis16 identified a mammalian nervous-
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system-specific membrane proteasome complex that directly and rapidly modulates
neuronal function by degrading intracellular proteins into extracellular peptides that
stimulate neuronal signaling through postsynaptic N-methyl-D-aspartate receptors.
Decreased proteasome function has been reported in a broad array of chronic
neurodegenerative diseases17. Impaired proteasome function has been implicated, as a
primary cause or a secondary consequence, in the pathogenesis of many
neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and Huntington’s
diseases2,17–21. In fact, brain region-specific proteasome inhibition (e.g., forebrain,
substantia nigra) closely mirrors the neuropathology and clinical hallmarks of
neurodegenerative diseases22–26. A small percentage of neurodegenerative disease is
caused by hereditary gene mutations, many of which affect components of the UPS (e.g.,
PARK1, PINK)20. However, the vast majority of neurodegeneration is idiopathic in origin
and the involvement of the UPS is less clear17. What is clear in these diseases is that
proteins that are normally degraded are not properly degraded after misfolding occurs,
leading to their accumulation. Several groups have provided evidence that aggregated
proteins from neurodegenerative diseases interact with and impair proteasome
function27,28,37,29–36. However, it is not clear what specific types of aggregates impair the
proteasome, and a mechanistic understanding of how they do so has not been elucidated.
Though, one study has been able to show that heterogeneous aggregates of the mouse
prion protein, PrPsc, reduced substrate entry by decreasing proteasomal gating36.
Despite these many efforts, an understanding of why and how the proteasome is so
generally impaired in neurodegenerative disease has remained elusive. Understanding
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the mechanism of impairment will provide a basis for drug development to restore
proteasome activity and proteostasis in the brain and is therefore an important effort.
Proteins targeted for proteasomal degradation are marked by the attachment of several
ubiquitin proteins. These poly-ubiquitinated substrates are recognized by the 26S
proteasome and are degraded9. The 26S proteasome is made up of a 20S proteasome
core particle capped on one or both ends by the 19S regulatory particle. It degrades
proteins by a multistep process: the 19S regulatory particle binds ubiquitinated substrates
and opens a substrate entry gate in the 20S38–40 and unfolds its substrates by
translocating them into the 20S catalytic chamber were they are degraded41,42. The 20S
is a hollow cylindrical complex composed of four heteroheptameric rings arranged in a
α7-β7-β7-α7 fashion43. Proteolysis occurs on the interior surface of β-subunit rings. The
substrate gate is formed by the N-termini of the α-subunits, which prevent unregulated
access to the catalytic sites by folding over the entry pore and blocking substrate
translocation into the catalytic chamber44. Triggering of gate opening by the 19S requires
the C-terminal HbYX motif of the 19S ATPases to bind to intersubunit pockets (between
the α-subunits) on top of the 20S45. The HbYX motif allows the 19S to bind to the 20S
core particle, but binding of the HbYX motif by itself (as a hepta peptide) is also sufficient
to allosterically induce conformational changes in the α-subunits that cause gate
opening45–48. Clearly, regulation of the 20S proteasome gate is an important aspect of
proteasome function and the cell has evolved many different proteasomal regulators that
control 20S gate opening, many of which contain the HbYX motif (e.g., the 19S ATPases:
Rpt2, Rpt3, Rpt5; Blm10/PA200; Pba1–Pba2; PI31; and archaeal CDC48/P97), and
some that do not (i.e., the 11S family: PA28αβ and PA26)48.
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This study demonstrates that misfolded proteins from three distinct neurodegenerative
diseases adopt a common three-dimensional (3D) conformation that is capable of
impairing ubiquitin-dependent and ubiquitin-independent proteasome function. Although
these oligomers possess unique primary sequences, they all impair the proteasome
through allosteric stabilization of the closed gated conformation of the 20S core particle,
therein blocking protein degradation. Moreover, these toxic oligomers specifically impair
HbYX motif dependent gate opening, yet do not impair gate opening induced by the 11S
family of regulators. These data suggest that proteasome impairment in various
neurodegenerative diseases may share a common mechanism.

RESULTS
Inhibitory oligomers share structural features
Prior studies report conflicting observations regarding the impairment of the proteasome
by disease-related aggregated proteins, some demonstrating proteasome impairment27–
35

while others do not49,50. The major limitation of these studies is that the conformational

state of the aggregates was not accounted for or considered. Aggregation-prone proteins
have the unique property of conformational polymorphism. During amyloid formation a
variety of aggregate species are formed, ranging from small dimers up to large insoluble
fibrils. Oligomers are metastable intermediates to fibril formation or an off-pathway
product of aggregation and are recognized as the primary pathogenic effectors5151. Since
the previous studies used heterogeneous compositions of the aggregated proteins, these
seemingly conflicting results for proteasome impairment are not surprising. In this study,
we purify to homogeneity a specific conformation of a pathological oligomer, identified its
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conformational status, and extensively characterize its mechanism of impairment on
human and mammalian 20S/26S proteasomes. In addition, this study identifies a specific
oligomeric conformation found in Alzheimer’s, Parkinson’s, and Huntington’s disease that
substantially impairs proteasome function in a way that could contribute to the
development and progression of these and other neurodegenerative diseases.
To determine if specific types of oligomers are responsible for proteasome impairment,
we began by generating various mixed populations of protein aggregates made from
either amyloid-β 1–42 (Aβ), α-Syn, or huntingtin exon 1 with a polyQ-expansion (Htt-53Q)
and asked if they could impair purified mammalian 20S proteasome. We found that under
specific oligomerization conditions (different for each protein type) each of the aggregate
preparations could significantly impair the 20S proteasomes ability to hydrolyze
fluorogenic peptide substrates (Fig. 1a). These results replicate those which have been
reported to some extent previously29–31. Next, we separated the mixed aggregates into
soluble and insoluble fractions and again tested their effect on proteasome activity. The
soluble oligomers, but not equal amounts of monomers or insoluble fibrils, strongly
impaired proteasome activity (Fig. 1b) in a concentration-dependent manner
(Supplementary Fig. 1). The eukaryotic proteasome has three types of active sites, each
displaying preference for cleavage after specific residues (chymotrypsin like,
hydrophobic; caspase like, acidic; trypsin like, basic). Substrate hydrolysis by all three of
the catalytic sites were impaired by the soluble oligomers (Supplementary Fig. 2).
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Figure 1. A specific conformation of soluble oligomers potently inhibits the mammalian 20S proteasome. a Mammalian 20S
proteasomes were incubated with mixed aggregates of Aβ1–42 (5 μM), α-Syn (1 μM), Htt-53Q (0.1 μM), or an equal volume of
oligomer buffer (control). Proteasome activity (linear rate of LLVY-amc hydrolysis) is represented as a percentage of activity
compared to the control. b Crude aggregates from a were separated into soluble and insoluble aggregates (schematic, left) and
were assayed as in a (bar graph, right). For huntingtin monomers, Htt-20Q monomers were used because pure Htt-53Q monomers
could not be obtained due to rapid oligomerization. Dot blots of monomers, soluble aggregates, and insoluble aggregates from b
were probed with the conformation-dependent anti-oligomer “A11” antibody (bottom right). c Soluble Aβ aggregates from b were
separated by size exclusion chromatography (Abs280 nm, solid blue line). Two microliters from each fraction was evaluated for its
effect on 20S proteasome chymotrypsin-like activity (bars) and probed for anti-oligomer A11 reactivity (dot blot, bottom). d
Proteasome activity with up to 5 μM of Aβ oligomers (Aβ-iO) or Aβ protofibrils (Aβ-PF) from c. e Intermediate oligomers from d were
pre-incubated with anti-oligomer A11 antibody (Aβ-iO + A11) or an equal volume of antibody buffer (Aβ-iO) for 30 min at 37 °C
before to addition to proteasome activity assay. Final concentration of Aβ-iO in the assay was 0.25 μM (the ~IC50 as determined in
d). The concentrations of aggregates are calculated based on the respective monomeric peptide/protein mass (Aβ, 4.5 kDa; α-Syn,
14 kDa; and Htt-53Q, 22 kDa). All controls contained an equal volume of buffer identical to that of the respective aggregates. The
data are representative of three or more independent experiments performed in triplicate. Error bars represent ± standard deviation
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Aβ, α-Syn, and Htt-53Q monomers are relatively unstructured and they can enter the 20S
proteasome to be degraded. However, the monomers fail to impair peptide hydrolysis by
the proteasome at equal concentrations as the oligomers (Fig. 1b) therefore, substrate
competition at the active site cannot explain impairment by the oligomers. Furthermore,
oligomers are too large (Fig. 2g, h) to enter the 13 Å wide substrate-entry channel of the
20S proteasome. Additionally, since the insoluble aggregates of these proteins cannot
impair the proteasome (Fig. 1b), this suggests that impairment by the oligomers may be
due to a specific conformation of the soluble oligomers, which is lost after conversion to
larger aggregates or fibrils. This is consistent with literature that ascribes cellular toxicity
to soluble oligomers in neurodegenerative diseases4,52,53. Many species of oligomeric
structures have been described, and antibodies developed to recognize specific structural
conformations of disease-related species54–56. Kayed et al.55 generated a polyclonal antioligomer antibody (A11) that specifically recognizes some types of protein oligomers
independent of the proteins amino acid sequence. This A11 antibody recognizes some
oligomeric species of Aβ, polyglutamine proteins, α-Syn, and prion, and has been used
to assess the presence of oligomers in diseased brains compared to aged matched
controls55,57. We performed a dot blot with A11 on the monomers, oligomers, and
insoluble fibrils for each protein that we tested. All three of the soluble oligomer
preparations contained the A11 epitope (A11+), while the epitope was absent in the
monomeric and fibril fractions (Fig. 1b bottom).
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Figure 2. Generation of stabilized A11+ oligomers (Ab*56) for mechanistic evaluation of proteasome inhibition. a Size exclusion
chromatography (Superose 6 GL 10/300) run that was used to generate a pure Aβ*56 oligomer preparation (blue solid line, left axis),
with proteasome activity (amc hydrolysis) from 1 μl of the corresponding fractions (bars, right axis; as in Fig. 1), and A11 dot blot
(bottom panel). b Native-PAGE Aβ*56 peak fraction from a followed by western blot using the A11 anti-oligomer antibody. c
Proteasome activity (LLVY-amc hydrolysis) with titrating Aβ*56; the IC50 is ~0.22 μM Aβ (4.5 kDa monomeric mass) or 18 nM Aβ*56
oligomer complexes (56 kDa mass each). d Representative raw data of proteasome activity assay (nLPnLD-amc hydrolysis) with
1.5 μM Aβ*56 oligomers (data point from c). e Change in polarization of FITC-labeled-casein protein (due to cleavage) in the presence
of the 20S proteasome, with and without 10 μM Aβ*56. f Rate of FITC-casein degradation (ΔmP/min). g Representative negative stain
electron microscopy image of purified Aβ*56 oligomers. Scale bar is 25 nm. h Representative tapping mode atomic force microscopy
topography image of Aβ*56 oligomers. Scale bar is 0.5 μm. Heat map for oligomer height is shown on the right. i ThT fluorescence of
the indicated Ab preparations. j, k Dot blot with A11 antibody i and oligomer native gel electrophoresis visualized by Coomassie stain k
of non-crosslinked and glutaraldehyde crosslinked (CL) Aβ*56 oligomers before and after 4-week incubation at 4 °C. l Proteasome
activity (nLPnLD-amc hydrolysis) in the presence of CL and non-crosslinked Aβ*56 oligomers (0.75 μM). Concentration of Aβ*56
oligomers is calculated based on the mass of peptide monomer (Aβ, 4.5 kDa). All controls contained an equal volume of buffer
identical to that of the respective aggregates. Proteasome activity was calculated as in Fig. 1a. The data are representative of three or
more independent experiments performed in triplicate. Error bars represent ± standard deviation. All following experiments utilize CL
Aβ*56 oligomers unless indicated otherwise

It is interesting that all three soluble oligomer types that impaired proteasome activity also
showed strong A11 antibody binding. To correlate proteasome impairment with the
presence of the A11 epitope more specifically, the soluble fraction of the Aβ aggregates
were separated by size exclusion chromatography (SEC). Three prominent populations
63

of soluble aggregates were observed, one in the void volume consistent with larger
protofibrils (Aβ protofibrils (Aβ-PF)), a second peak corresponding to intermediate-sized
oligomers (Aβ-iO), and a third pool of small oligomers and monomers (Fig. 1c
chromatogram). The effect of each fraction on 20S proteasome activity was determined.
Only the intermediate-sized oligomers (~56 kDa) impaired the 20S proteasome (Fig. 1c
bars) and this impairment correlated with the fractions that were positive for A11 (Fig. 1c
dot blot). This inhibitory species also impaired the degradation of fluorogenic substrates
specific for each of the 20S’s three different proteolytic sites as observed in the mixed
oligomer populations (Supplementary Fig. 3A). This suggests that impairment could be
due to impairment of substrate entry rather than impairment of a specific catalytic active
site. The Aβ protofibril peak (Aβ-PF), lacking the A11 epitope, did not impair degradation
of any fluorogenic substrates, even in the presence of ten times more Aβ-PF than Aβ
intermediate oligomers (Fig. 1d and Supplementary Fig. 3B).

It is plausible that proteasome impairment is due to the oligomer size rather than a specific
oligomeric structure. To determine if the impairment is due to the size of the
oligomer/protofibrils and whether the shared A11 reactivity is merely a coincidence, we
generated

high-molecular

weight

(200–400 kDa)

A11+

Aβ

oligomers

(Aβ-iO)

(Supplementary Fig. 4A) and A11+ Aβ-PF (>700 kDa) (Supplementary Fig. 5A). The high
MW A11+ Aβ-iO impaired the 20S commensurate with the level of A11 reactivity
(Supplementary Fig. 4A & B). The higher molecular weight A11+ Aβ-PF also impaired
substrate hydrolysis by all three active sites of the proteasome (Supplementary Fig. 5B),
although to a considerably lesser extent than the intermediate Aβ-iO (Fig. 1d). This is
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expected based on the proposal that protofibrils form when the oligomers bind to one
another to form a chain of oligomers58, which sterically blocks surfaces on the internal
oligomers but not the terminal ones, which could still interact with the proteasome. To
further determine if the structural epitope of the A11 antibody on the intermediate Aβ-iO
is necessary for proteasome impairment we performed a neutralization assay to block the
A11 epitope. A11+ oligomers were incubated with the A11 antibody prior to testing
proteasome activity. Aβ-iO were used at a concentration of 0.2 μM, the IC50, as
determined in Fig. 1d, so an increase or decrease in proteasome activity could be readily
observed. Indeed, the A11 antibody when bound to the Aβ-iO completely rescued
proteasome activity (Fig. 1e). As a control, the experiment was repeated with an antibody
raised against the N-terminal residues of Aβ (clone NAB228), which did not rescue
proteasome function (Supplementary Fig. 6). This demonstrates that an available
oligomer-specific A11 epitope site is necessary for impairment of the proteasome.

Characterization of homogenous and stable oligomers
Above we described the isolation of a specific proteasomal inhibitory oligomer from a
mixed population of oligomers and aggregates. In order to determine the mechanism of
impairment we sought to generate homogenous, stable, and reproducible A11+
oligomers, which could be used for reliable mechanistic analysis. In contrast to α-Syn and
huntingtin aggregates, methods to generate physiological relevant oligomers from
synthetic Aβ peptides have been extensively developed. Barghorn et al.59 characterized
a highly stable Aβ (1–42) oligomer species (~dodecamer) which can be prepared in vitro
and can be found in the brains of patients with AD. The relevance of dodecameric Aβ-iO
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to disease pathology is established57,60. With some modifications to the protocol of
Barghorn et al.,59 we generated Aβ*56 oligomers, and purified them by nondenaturing
SEC (Fig. 2a chromatogram). The major peak corresponds to the intermediate-sized AβiO in Fig. 1d. We tested each fraction for proteasome activity and found the major peak
impaired the 20S (Fig. 2a bar graph). The single symmetric protein peak demonstrates
the homogenous nature of the oligomer preparations. Consistent with Aβ*56 oligomers
isolated from human brain tissue and cerebrospinal fluid, our Aβ*56 oligomers are A11+
(Fig. 2a), run at ~56 kDa (Fig. 2b)57, and significantly impair proteasome activity in a
concentration-dependent manner (Fig. 2c). Representative real-time fluorogenic
substrate hydrolysis data are also shown (Fig. 2d).

Since Aβ*56 can impair 20S peptide substrate degradation, we asked if it could impair
protein degradation as well. The 20S core particle by itself cannot unfold proteins, so we
used β-casein, a classical unfolded protein substrate. We used FITC-labeled casein to
follow its degradation in real time using anisotropy, which monitors the tumbling rate of
the fluorophore. When FITC-labeled casein is degraded by the proteasome, the tumbling
rate of the fluorophore increases, causing a decrease in anisotropy (Fig. 2e 20S + buffer).
Similar to peptide substrates, purified Aβ*56 oligomers also impaired proteasome
degradation of the FITC-labeled casein protein (Fig. 2e 20S + Aβ*56), demonstrating that
Aβ*56 also impairs the degradation of an unfolded protein. We confirmed that the relevant
morphology of these oligomers were consistent with those published for synthetic and
human brain derived oligomers via: native gel electrophoresis57,61 (for MW), transmission
electron microscope (TEM)62 (for spherical shape), atomic force microscopy (AFM)63,64
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(for size), Thioflavin-T (ThT) staining55 (slight but low staining), and anti-oligomer immunodetection57 (Fig. 2g–i).

Oligomers are metastable intermediate structures, which complicates analysis when
consistent homogeneous preparations are need for in-depth biochemical analysis. To
circumvent this issue, we stabilized the Aβ*56 oligomers by crosslinking, which
maintained the conformation of the A11+ epitope for 4 weeks when stored at 4 °C (Fig.
2j) and without crosslinking the A11+ epitope was not as stable over this time period. In
addition, the apparent mass of the crosslinked (CL) oligomers was also assessed via
Native-PAGE and we found that it was unchanged over the 4-week incubation (Fig. 2k).
The CL Aβ*56 oligomers ran slightly faster than the non-crosslinked oligomers as
expected59, likely due to stabilization of the CL structure. In contrast, the non-crosslinked
oligomers partially dissociated into smaller oligomers and formed larger oligomers after 4
weeks (Fig. 2k). Most importantly, crosslinking of the oligomers does not alter their
proteasome impairment activity compared to the non-crosslinked form (Fig. 2l). Together,
this demonstrates that the synthetic Aβ*56 oligomers are homogenous, relevant, stable,
reproducible, and represent a single oligomeric species that potently impairs peptide and
protein degradation by the 20S proteasome. These CL Aβ*56 oligomers are therefore
ideally suited for further mechanistic and biochemical analysis to understand how
oligomers impair proteasome function and are thus used in all the following experiments
using Aβ-iO unless stated otherwise.
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Direct binding of Aβ*56 to 20S proteasome
We next sought to determine if Aβ*56 and the 20S proteasome could be observed to
directly interact. Non-crosslinked Aβ*56 oligomers were mixed with purified 20S
proteasomes. To stabilize their interaction, we used a low concentration of glutaraldehyde
(1 mM) to induce crosslinking and analyzed migration. Aβ*56 is clearly seen co-migrating
with the 20S proteasome by Native-PAGE gel visualized with both silver stain (Fig. 3a
left) and by immunoblotting for total Aβ (Fig. 3a right). Notably, the low concentration of
glutaraldehyde treatment did not cause random non-specific protein crosslinking and did
not crosslink the entire multisubunit proteasome into a single 700 kDa complex as
determined by the absence of protein aggregates in the SDS-PAGE stacking gel
(Supplementary Fig. 7). Minimal crosslinking conditions are further demonstrated by the
discrete banding pattern of multiple subunits and the persistence of two single subunit
bands (Supplementary Fig. 7).
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Figure 3. The A11(+) oligomers bind to the 20S proteasome and impair opening of the substrate gate. a 20S
proteasomes (0.4 μg) and pure non-crosslinked Aβ*56 oligomers (1.5 μg) were incubated separately or together for
30 min (37 °C), crosslinked with 1 mM glutaraldehyde for 5 min, and separated by Native-PAGE (4–8% Tris–acetate
gel). Total protein was detected by silver stain (left), and total Aβ was detected by western blot (right). b–d The activity
of yeast 20S wild-type (WT) and open-gate (α3ΔN) proteasomes was measured for all three proteolytic sites in the
presence of A11(+) oligomers from Aβ*56 (b; 2.5 μM), α-Syn (c; 100 nM), and Htt-53Q (d; 50 nM). Chymotrypsin-like
activity was measured by LLVY-amc hydrolysis, trypsin-like activity by RLR-amc, and caspase like by nLPnLD-amc
hydrolysis. The concentrations of aggregates are calculated based on the respective monomeric peptide/protein mass.
All controls contained an equal volume of buffer identical to that of the respective aggregates. The data are
representative of three or more independent experiments performed in triplicate. Error bars represent ± standard
deviation

Toxic oligomers impair proteasome gate
Substrates must pass through the gated translocation channel before gaining access to
the proteolytic sites44. The A11+ oligomers are too large to enter the 13 Å translocation
channel and directly inhibit β-subunit active sites; however, they could be impairing 20S
proteasome function by impairing substrate entry through the gate or by allosterically
impairing the active sites. To address this question, we used the α3ΔN proteasome
mutant, which has a constitutively open gate65. If the oligomers impair proteasome activity
by clogging the catalytic chamber or allosterically impairing the active sites, then they
should be able to impair the proteasome regardless of if its substrate gate is in the opened
or closed state. Alternatively, if the oligomers require a functioning gate for impairment,
then they should not be able to impair a proteasome with a constitutively open gate, i.e.,
the α3ΔN 20S proteasome, which lacks only one of its seven α-subunit N-termini44. We
added the three different A11+ oligomers: Aβ*56, α-Syn, and Htt-53Q, to the wild-type
(WT) or the α3ΔN 20S proteasome and monitored substrate degradation. All three A11+
oligomers significantly impair WT proteasomes but do not impair the α3ΔN proteasomes
(Fig. 3b–d). These results demonstrate that the A11+ oligomers require a functioning gate
in order to impair the 20S proteasome. In addition, most active site proteasome inhibitors
only inhibit one or two proteolytic sites, but the A11+ oligomers impair the degradation of
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substrates specific for each of the three different catalytic sites (Fig. 3b–d), further
supporting a gating mechanism of impairment, since restricting substrate access would
be expected to impair all types of substrates. Moreover, a translocation channel clogging
mechanism can also be ruled out since the α3ΔN 20S proteasome could not be impaired.
To further confirm an allosteric mechanism of proteasome impairment, we performed a
substrate saturation curve on the WT 20S proteasome with and without Aβ*56 oligomers.
We used nonlinear regression and the Michaelis–Menten equation to analyze the KD and
Vmax of the two curves. We found that the Aβ*56 oligomers caused a decrease in the
Vmax and an increase in the Km (Supplementary Fig. 8), which is consistent with
allosteric inhibition (i.e., mixed inhibition—a form of noncompetitive inhibition). Taken
together, these data clearly demonstrate that all three diseases-related oligomers impair
proteasome function by a similar allosteric mechanism, since all three A11+ oligomers
require a closable gate on the 20S proteasome to impair it.

To validate the preparation of the open-gate α3ΔN 20S proteasomes, they were
incubated with either a known gate-opening peptide (KANLQYYA45 from the C-terminus
of Rpt5, which includes the HbYX motif) or the β-subunit active site inhibitor, MG132.
Treatment with MG132 completely inhibits WT and open-gate α3ΔN proteasomes
(Supplementary Fig. 9A) as expected for a pure proteasome preparation. The Rpt5
peptide increases WT 20S proteasome substrate degradation but failed to stimulate the
open-gate α3ΔN 20S proteasome (Supplementary Fig. 9B) as expected for proteasomes
with constitutively open gates. The preparations of pure α3ΔN 20S were approximately
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ten times more active than the WT 20S and thus ten times more WT 20S was used in
these experiments to obtain comparable basal rates (Supplementary Fig. 9).

Toxic oligomers stabilize the closed gate conformation
Binding of the 19S ATPases C-termini HbYX motif into the 20S intersubunit pockets
induces a conformational change of the 20S α-subunits, which stabilizes the open state
of the N-terminal gating residues9,45. However, recent cryo-EM studies have highlighted
the complexity of this gate-opening mechanism in the 26S proteasome when the 19S
binds to a substrate (or when it is switched from an ATP-bound state to an ATPγS bound
state)66,67. It is less clear how the dynamics of the gate changes when the 19S associates
with the 20S. Nevertheless, functional studies have shown that 19S binding to the 20S
stimulates gate opening in the 20S proteasome39,40 in a HbYX motif dependent manner47.
In contrast, the 11S family of proteasome activators (e.g., PA28α/β and PA26) bind to the
20S α-subunits and facilitate gate opening by a different mechanism. Although the 11S
subunits also bind to the α-intersubunit pockets, they lack the HbYX motif and thus do not
induce α-subunit conformational changes like the HbYX motif does. Instead, the 11S
internal “activation loop” is required for gate opening. This “activation loop” directly
contacts the base of the N-terminal gating residues and locally repositions them into the
open conformation68.

We hypothesized that binding of the A11+ oligomers to the 20S may specifically impair
one of these distinct gate-opening mechanisms, which would provide evidence for the
mechanism of oligomer-mediated proteasome impairment. If the oligomers could impair
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the PA26–20S complex, then it is expected that they would bind to the top of the 20S and
compete with PA26 for binding to the 20S. Alternatively, if the oligomers do not compete
with PA26 for binding to the 20S but they do impair the HbYX-dependent gate opening
this indicates that oligomers must allosterically affect conformational changes that are
caused upon HbYX motif binding. Another possibility is that the oligomers affect both or
neither mechanism of gate opening. To assure that both ends of the 20S proteasome
were bound by PA26 we used saturating amounts to stimulate 20S peptide degradation.
None of the A11+ oligomers from Aβ, α-Syn, or Htt-53Q could impair the PA26–20S–
PA26 complex (Fig. 4a–c). Thus, the PA26–20S–PA26 complex mirrors the results
obtained for the α3ΔN 20S. To evaluate this possibility that the oligomers compete with
PA26 for binding to the 20S, we generated a binding saturation curve for PA26 to 20S by
monitoring 20S proteasome activation in the presence and absence of A11+ Aβ*56
oligomers. The apparent affinity of PA26 binding for the 20S did not decrease in the
presence of the A11+ oligomers (Fig. 4d) and the oligomers did not impair PA26 at any
concentration that was used, indicating that the oligomers do not compete with PA26 for
binding to the 20S. In addition, the Aβ*56 oligomers could not impair PA26 mediated gate
opening even at very high Aβ*56 concentrations (Fig. 4e). The PA28αβ proteasome
activator from humans is a homologue of PA26 and thought to open the 20S gate in a
similar activation loop-dependent manner68. Consistent with PA26 results, the A11+
Aβ*56 oligomers could not impair the human PA28αβ-mediated proteasome gate opening
(Fig. 4f). Therefore, the A11+ oligomers bind to the 20S proteasome at a location separate
from the 11S proteasome activators, PA26 and PA28αβ. Based on this we hypothesized
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that the oligomers stabilize the latent closed conformation of the α-subunits, which is not
affected by the PA26/28 activation loop-dependent gate opening.
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Figure 4. A11(+) oligomers cannot inhibit PA26 or PA28αβ induced gate opening. a–c 20S Proteasome activity with and without
the proteasome activator PA26 (1 μg/100 μl) was determined in the presence of A11(+) oligomers from Aβ*56 (1.5 μM, a), α-Syn
(0.1 μM, b), or Htt-53Q (0.1 μM, c). Broken graphs are used to show the extent of 20S inhibition, while still showing the extent of
PA26 activation. d Proteasome activity in the presence of increasing concentrations of PA26 with and without A11(+) Aβ*56
(1.5 μM). The sigmoidal equation was fit to the averages from three independent experiments (normalized to % activity) performed
in triplicate, error bars ± SEM. For a–d, the 20S proteasome activity (nLPnLD-amc hydrolysis, rfu/min) was normalized to 20S
control activity without activator. e Proteasome activity with PA26 activator (1 μg/100 μl) in the presence of increasing
concentrations of Aβ*56 (left). Activity of 20S proteasome (without PA26) with 1.5 μM Aβ*56 is shown at right. f Same experiment
as in a, with human PA28αβ replacing PA26. The concentrations of oligomers are calculated based on the respective monomeric
peptide/protein mass. All controls contained an equal volume of buffer identical to that of the respective aggregates. The data are
representative of three or more independent experiments performed in triplicate. Error bars represent ± standard deviation
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To test this hypothesis, we asked if the A11+ oligomers could impair peptide and protein
degradation by purified human 26S proteasomes. The A11+ Aβ*56 oligomers significantly
impaired peptide degradation by the purified 26S proteasome compared to controls (Fig.
5a). To further test this possibility, we determined if oligomers could impair ubiquitindependent (Ub4(lin)-GFP-35) protein degradation by purified human 26S proteasomes.
The Ub4(lin)-GFP-35 substrate we used to monitor ubiquitin-dependent degradation is a
circularly permuted GFP with a linear tetra ubiquitin on N-terminus and a 35-residue
unstructured region on the C-terminus that was created in the Matousheck lab. We found
that Aβ*56 also strongly impaired the degradation of this structured protein (Fig. 5b, c) by
the human 26S proteasome, which requires ATP-dependent unfolding and injection into
the 20S core. These data suggest the oligomers impair the HbYX mechanism of gate
opening. However, it is possible that the oligomer binding to the 20S could cause the 26S
to disassemble into its 20S and 19S subcomplexes, which could also have the effect of
impairing the ubiquitin-dependent protein degradation that we observed. To test this
possibility, we incubated Aβ*56 oligomers and purified human 26S proteasome
preparations together for 90 min at 37 °C before running the samples on native-PAGE
(Fig. 5d). We quantified the silver stain band densities for isolated 20S, singly capped
26S, and doubly capped 26S. The relative ratio of these three populations of proteasomes
did not change with the incubation with Aβ compared to control.
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Figure 5. Aβ*56 oligomers inhibit ubiquitin-dependent and ubiquitin-independent degradation of full-length proteins. a–d Purified
human 26S proteasomes. a Human 26S proteasome activity (LLVY-amc hydrolysis, rfu/min) with 2 μM Aβ*56 compared to buffer
control. b Change in fluorescence of polyubiquitin-GFP fusion protein (Ub4(lin)-GFP-35) in the presence purified human 26S
proteasome, with and without 5 μM Aβ*56. c Rate of polyubiquitin-GFP fusion protein (Ub4(lin)-GFP-35) degradation in c (Δrfu/min). d
Purified human 26S proteasomes were incubated with or without Aβ*56 for 90 min at 37 °C, and separated by Native-PAGE and silver
stained. Band density was quantified with ImageJ. Band density is shown as a percentage of total density of each lane. e–h Full-length
protein degradation in mouse brain lysates. e Change in polarization of FITC labeled-casein in 2 μg mouse brain lysates, with and
without 10 μM Aβ*56. f Rate of FITC-casein degradation in e (ΔmP/min). g Change in fluorescence of polyubiquitin-GFP fusion protein
(Ub4(lin)-GFP-35) in 2 μg mouse brain lysates, with and without 10 μM Aβ*56. h Rate of polyubiquitin-GFP fusion protein (Ub4(lin)GFP-35) degradation in g (Δrfu/min). The concentration of Aβ*56 oligomers is calculated based on Aβ monomeric peptide mass
(4.5 kDa). All controls contained an equal volume of buffer identical to that of the Aβ*56 oligomers. The data are representative of three
or more independent experiments performed in triplicate. Error bars represent ± standard deviation
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The prior experiments were done with highly purified components thus providing good
cause and effect confidence for mechanistic analysis; however, the purified system
cannot assess if the oligomers are able to bind to and impair the proteasome in an
environment that more closely mimics a complex cellular environment. To address this,
we prepared mouse brain lysates to determine if the toxic oligomers could still impair
protein degradation by the proteasome in such a heterogeneous environment. We found
that the brain lysates were highly competent to degrade the protein substrates FITCcasein (Fig. 5e, f) and Ub4 (lin)-GFP-35 proteins (Fig. 5g, h) similar to the purified 26S
proteasome (Fig. 5b-c). We also assessed the proteasome activity component of this
lysate by adding the proteasome inhibitor MG132, and found that the majority of the
degradation activity, we observed was due to proteasome activity (Fig. 5e–h). When we
assessed the degradation of these two-specific proteins in brain lysates, in the presence
of the crosslink-stabilized Aβ*56, we observed extensive proteasome impairment—nearly
as much as when MG132 was used (Fig. 5e–h). Therefore, the A11+ Aβ*56 oligomers
retain enough specificity to bind to and nearly completely impair proteasome function
even in a complex brain lysate. These data demonstrate that the oligomers do not disrupt
the 26S complexes, and thus do not impair it by this mechanism, but must instead act, as
we expected, on the gate. Impairment of the 26S proteasome also demonstrates that the
oligomers must bind to the 20S even in the presence of the 19S, as was also observed
for the PA26–20S complexes, demonstrating that the oligomers likely bind to the outer
surface of the 20S proteasome (i.e., not on the gating surface) thus supporting the
hypothesis that these toxic oligomers act allosterically preventing the 20S gate from
opening properly. Since these results clearly demonstrate that A11+ oligomers are able
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to impair the 20S core particle by itself, then it is most likely that their impairment of the
26S proteasome is via the same mechanism, acting on the core particle. Importantly, this
result demonstrates that A11+ oligomers can also impair proteasome function in a
complex protein environment.
The 19S requires binding of ATP for
it to bind to and induce gate opening
in the 20S69. The 26S proteasome
adopts

multiple

conformations

during the ATP hydrolysis cycle and
substrate degradation66,70–72. In the
presence of hydrolysable ATP, 26S
proteasomes seems to alternate
between active (open gate) and
inactive (closed gate) states, with the
inactive state predominating, and in
Figure 6. HbYX-dependent 20S gate opening counteracts inhibition
by Aβ*56 oligomers. a Mammalian 26S proteasome activity (LLVYamc hydrolysis, rfu/min) with 2 mM ATP or 10 μM ATPγS. Aβ*56
titration up to 6 μM. b 20S proteasome activity (nLPnLD-amc
hydrolysis, rfu/min) with RPT5 peptide titration, with and without Aβ*56
(0.5 μM). c Schematic depicting our working model for proteasome
inhibition by A11(+) oligomers (see text for details). The concentration
of Aβ*56 oligomers is calculated based on Aβ monomeric peptide
mass (4.5 kDa). All controls contained an equal volume of buffer
identical to that of the Aβ*56 oligomers. The data are representative of
three or more independent experiments performed in triplicate. Error
bars represent ± standard deviation

contrast,

non-hydrolyzing

ATP

analogues better stabilize the active
(open

gate)

form

of

the

proteasome66,73. Interestingly, while

the Aβ*56 oligomers impaired the 26S in the presence of ATP, they could not impair the
26S in the presence of the analog ATPγS (Fig. 6a). This shows that the oligomers are
able to impair the normal physiological (with ATP) state of the 26S but not the synthetically
opened state (using ATPγS), in which the open state is more “strongly” stabilized. We
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verified the integrity of the purified 26S proteasomes preparation via Native-PAGE to
confirm that the observed activity came only from the 26S complexes (Supplementary
Fig. 10) and not from any free 20S proteasome in the preparation. These results thus
further support the hypothesis that these oligomers oppose the HbYX-dependent
conformational changes that lead to gate opening.
To further test this hypothesis, we asked if the A11+ oligomers could block HbYXdependent gate opening directly by the Rpt5 peptide (KANLQYYA), an established gate
opening peptide4545, derived from the C-terminus of Rpt5. We added increasing
concentrations of the Rpt5 peptide to the 20S proteasome with and without the A11+
Aβ*56 oligomers. In the absence of oligomers, the Rpt5 peptide significantly stimulated
proteasome activity as expected. However, the oligomers impaired Rpt5 activation at all
concentrations. Interestingly, the more Rpt5 was added the less effective the oligomers
were to impair the proteasome (Fig. 6b). These results indicate that the oligomers impair
HbYX-dependent gate opening, but also that HbYX peptide could overcome impairment
by the oligomers at the higher concentrations (1 mM Rpt5 peptide was the highest
concentration that could be tested due to its solubility). In contrast, the oligomers could
not impair PA26 activation at any concentration of PA26. We interpret these results to
mimic the ATP/ATPγS experiment (Fig. 6a), whereby the ATP state is a low HbYX
occupancy state and the ATPγS state is a higher occupancy HbYX state. The rational is
that ATP is rapidly hydrolyzed to ADP, and ADP cannot support HbYX-dependent gate
opening. On the other hand, ATPγS is not hydrolyzed to ADP and thus it sustains the
HbYX bound open-gate state or it could also enhance gate opening by other
mechanisms73. These combined results fit well with a model, whereby the A11+ oligomers
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impair proteasome function by binding to the outer surface of the 20S barrel and impair
substrate entry by allosterically stabilizing the closed conformational state of the 20S αsubunits, in a way that directly counteracts the conformational changes that are required
for HbYX-dependent gate opening.

DISCUSSION
The structural evolution of compartmentalized proteases was driven by the need to
protect proteolytic activity from the cellular milieu, but still have the capacity to degrade
select proteins in a regulated manner. The substrate-entry gate in the 20S proteasome
thus plays a critical role in proteasome function and in cellular proteostasis. Here, we
elucidate a common mechanism whereby soluble oligomers possessing a common 3D
structure found in many neurodegenerative diseases potently inhibit 20S and 26S
proteasome gate opening thus drastically impairing its function. While certain studies
show some forms of aggregates do not impair the proteasome (which we also find Fig.
1b, d), the aggregates from these studies were not assayed for the presence of A11+
oligomers. Based on our results we proposed the following mechanistic model (Fig. 6c)
of how A11+ oligomers impair proteasome function: (1) A11+ oligomers bind with low
nanomolar affinity (Figs. 1 and 2) to the outer surface of the α-subunits along the C2 axis
(the presumed binding site); (2) by binding to this site the oligomers stabilize the closed
conformation of the α-subunits and prevent spontaneous gate opening (Fig. 3); (3)
activation loop-dependent gate opening (e.g., PA26) occurs normally in the presence of
oligomers, since its mechanism only requires contact between the activation loops and
the base of the gating residues (Fig. 4); (4) however, HbYX-dependent gate opening (e.g.,
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the 19S regulatory particle or HbYX peptide) is inhibited as oligomer-bound α-subunits
are unable to undergo the conformational changes required to open the gate (Figs. 5 and
6), which are stabilized by the bound oligomer. From a general mechanistic perspective,
in this model one expects to observe opposing allosteric controls fought between two
allosteric modulators that bind to distinct sites on the 20S proteasome. From this model,
one expects to observe competition between two allosteric modulators (the HbYX motif
and the oligomers) that bind to distinct sites on the 20S proteasome. In this sense, the
HbYX motif is a positive allosteric modulator that induces gate opening, whereas the A11+
oligomers are negative allosteric modulators that induce gate closing. These diametrically
opposed regulators thus fight to control the proteasome gate. Moreover, it appears that
the HbYX mechanism is dominant since binding of the non-hydrolysable ATP analog,
ATPγS, prevents inhibition by A11+ oligomers (Fig. 6a), though further confirmation is
warranted.

These results demonstrate that oligomer-mediated impairment of proteasome function is
not dependent on the sequence of the misfolded protein but rather the oligomer’s 3D
shape. Specifically, we found a consistent correlation between an oligomer’s ability to
impair the proteasome and recognition by the A11 antibody. While the physiological
concentration of A11+ oligomers in neurons is unknown, if we consider that the affinity
constant for the oligomers is low nanomolar, and that the cellular concentration of the 20S
is estimated to be low micromolar74 then, with respect to this binding reaction, the 20S is
saturating in the cell. This implies toxic oligomers will bind to the 20S irrespective of their
cellular concentration, which begs the question: are the physiological levels of A11+
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oligomers sufficient to impact protein degradation? Using laser capture microdissection
and isolation of hippocampal pyramidal neurons from sporadic Alzheimer’s Disease
cases, Hashimoto et al.75 determined the intraneuronal concentration of Aβ42 to be 3 μM,
but what proportion of the intracellular Aβ42 is in oligomeric form is not known.
Furthermore, Kisselev et al.76 showed that the amount of proteasome inhibitor, Velcade™
that is used to treat multiply myeloma only inhibits protein degradation by about 10–25%.
This result demonstrates that a relatively small alteration of protein breakdown can have
a substantial impact on cell death. Consistent with this reasoning, stereotaxic unilateral
infusion of lactacystin (a selective proteasome inhibitor) into the substantia nigra pars
compacta of rats caused neurodegenerative disease like symptoms22. However, the
percentage of proteasomes that must be active in neurons to maintain normal
proteostasis is not known and thus we could only speculate about what level of
intracellular A11 oligomers would be required to impact neuronal function. Nevertheless,
as protein degradation begins to suffer as oligomers accumulate, the level of proteasome
impairment is expected to increase exponentially as more proteins accumulate and
oligomerize. Such a model would be expected to exhibit exponential progression kinetics,
which coincides with the exponential deterioration that is observed over decades in most
neurodegenerative diseases. These results build confidence that such oligomers in
neurons could impair proteasome function enough to contribute to the progression of
these neurodegenerative diseases.

Future efforts are required to understand which structures within the A11 epitope facilitate
20S proteasome binding and impairment and if this phenomenon occurs in human
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disease conditions. Elucidation of this mechanism provides a compelling model to explain
why proteasome function has been found to be impaired in virtually all neurodegenerative
diseases. Interestingly, Choi et al.77 showed that opening of the 20S proteasome gate in
cells leads to enhanced cellular proteasome function, including ubiquitin-dependent
protein degradation, decreased protein aggregates, and protection from oxidative stress.
Our model provides a mechanistic framework to develop small molecules to counteract
proteasome impairment via A11+ oligomers. Illustrating this potential mechanism of
proteasome impairment identifies novel drug targets for developing small molecule
activators of the proteasome gate. Such therapeutic interventions have the potential to
restore proteostasis in patients suffering from neurodegenerative diseases.

METHODS
Proteasome purifications
Mammalian 20S proteasomes were isolated from bovine liver as described78. Briefly,
cleared liver homogenate was passed over DE53 column. Protein was eluted with a
stepwise NaCl gradient. Fractions with significant proteasome activity were pooled and
further separated by a strong anion-exchange column (ResourceQ, GE Healthcare)
eluting with NaCl gradient. Fractions with high suc-LLVY-amc hydrolysis were pooled for
further purification using a hydroxyapatite column (CHT-I, Bio-Rad) and eluted by KPO4
gradient. Fractions with high proteasome activity were pooled and further purified by SEC
(S-400, GE Healthcare). Eluted fractions were pooled and purity of 20S proteasomes
(>98%) was determined by SDS-PAGE and quantified by densitometry (ImageJ, NIH).
Mammalian 26S proteasomes were isolated from rabbit muscle using the Ubl affinity
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purification as described79. Human 26S proteasomes were affinity purified on a
streptavidin column from the HEK293-β4-biotin cell line as described77. Recombinant
PA26 was expressed in BL21-STAR Escherichia coli and purified by affinity with a NiNTA column (Qiagen), as described80. Recombinant human PA28αβ was expressed in
BL21-STAR E. coli and purified by affinity with a Ni-NTA column (Qiagen), as described81.
WT and mutant α3ΔN yeast 20S proteasomes were expressed and purified by anionexchange chromatography as described82. Fluorogenic substrate peptides were
purchased from BostonBiochem (suc-LLVY-amc) and EZBiolabs (ac-nLPnLD-amc and
ac-RLR-amc). Rpt5 peptides were synthesized by EZBiolabs. Protein concentrations
were determined by Bradford assay (Thermo Scientific).

Proteasome activity assays—peptide substrates
Unless otherwise specified, bovine 20S (0.5 nM), rabbit muscle 26S (0.4 nM), yeast WT
20S (1.4 nM), or yeast α3ΔN 20S (0.14 nM) proteasomes were assayed using fluorogenic
peptides, as described45 in 96-well black flat bottom untreated plates (Costar). Briefly,
proteasomes were incubated in a reaction buffer containing 50 mM Tris–HCl (pH 7.4),
and 100 μM fluorogenic substrate (suc-LLVY-amc, ac-nLPnLD-amc) or 10 μM fluorogenic
substrate (boc-LRR-amc). 20S proteasomes were treated with Rpt5, or with PA28αβ or
PA26 to induced gate opening as indicated. Rabbit muscle 26S proteasomes were used
in the presence of 1 mM DTT, 10 mM MgCl2, and 100 μM of fluorogenic substrate (acnLPnLD-amc) with either 2 mM ATP (99%, Sigma) or 10 μM ATPγS (95%, Sigma).
Fluorescence was measured every 55S for 120 min (ex/em: 380/460 nm). The rate of
increase in fluorescence intensity is directly proportional to proteasome activity. For all
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experiments, an equal volume of the appropriate control buffer (identical to the
aggregate/oligomer buffer that is described below) was used for controls. All molar
concentrations of Aβ, α-Syn, and Htt-53Q are calculated based upon the monomeric
protein concentration.

Proteasome activity assays—protein substrates
FITC-casein (0.08 μg, Sigma) and Ub4(lin)-GFP-35 (0.08 μg, a kind gift from Dr. Andreas
Matousheck) degradation assays were carried out in 50 μl reactions using 96-half-well
non-binding surface treated black plates (Corning) at 37 °C. The GFP substrate was
generated as described83. Proteasomes were added to the reactions (1 μg 20S, or 0.9 μg
human 26S) in the presence or absence of Aβ*56 oligomers (10 μM) and fluorescence
was measured at every 60 s for 90 min. The data shown are the mean of three reactions,
with a five-point moving average, and error bars represent ± standard deviation.
Degradation rates were determined by calculating the slope of a line fit to the first 30 min
of activity.

Aβ1–42
Synthetic Aβ(1–42) was purchased from Selleckchem, Anaspec, and EZBiolabs. To
remove preexisting aggregates, synthetic Aβ peptide was dissolved in 100%
hexafluoroisopropanol (HFIP) and incubated at 37 °C for 2 h with shaking (500 rpm). The
HFIP was removed, and the remaining peptide films were stored at −80 °C until use.
Monomeric Aβ was obtained by dissolving synthetic peptide in 100% anhydrous dimethyl
sulfoxide (DMSO) (Thermo Scientific) at 5 mM and diluted with phosphate-buffered saline
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(PBS) to a final concentration of 50 μM immediately prior to use. Crude Aβ aggregates
were prepared as described84. Aβ*56 oligomers were generated similar to Barghorn et
al.59. Briefly, HFIP-treated peptide films were resuspended in 100% anhydrous DMSO
(5 mM) and bath sonicated for 20 min before further dilution (400 μM) with 20 mM NaPO4
pH 7.4, 140 mM NaCl, 0.2% SDS. The 100 μM Aβ was incubated at 37 °C for 6 h, diluted
to 100 μM with ddH2O, incubated at 37 °C for 18 h, centrifuged for 10 min at 3000×g, and
the supernatant containing Aβ*56 oligomers was removed and dialyzed against 5 mM
NaPO4 pH 7.4, 35 mM NaCl. Where indicated, Aβ*56 oligomers were CL (before dialysis)
with 1 mM glutaraldehyde (EM grade, Thermo Scientific) for 2 h at room temperature. The
reaction was quenched by the addition of 1 M Tris–HCl pH 8 (to a final concentration of
10 mM) and incubated for an additional 30 min. Aβ*56 oligomers were purified by SEC
(Superose 12 10/30, GE Healthcare) and eluted as a single major peak. Each preparation
of Aβ*56 was confirmed to be A11+ by dot blot analysis as described below. To generate
Aβ-HMW A11+ oligomers, the second Aβ incubation at 100 μM was extended to 26 h. To
generate Aβ A11+ protofibrils, the second Aβ incubation at 100 μM was extended to 50 h.
The Aβ A11+ protofibrils eluted from the Superose 6 column in a single peak at the void
volume and were confirmed to be >700 kDa by Native-PAGE. All buffers were filtered with
0.2 μm membranes immediately prior to use. All SEC experiments were performed on an
ÄKTApurifier (GE Healthcare) at 4 °C with 5 mM NaPO4 pH 7.4, 35 mM NaCl at a flow
rate of 0.5 mL/min. Aβ concentration was calculated by UV absorption at 280 nm (molar
extinction coefficient 1940 M/cm) and confirmed with Bradford protein concentration
assay (Thermo Scientific).
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α-Syn protein
Human WT α-Syn with N-terminal his-tag in pET28a vector was expressed and purified
from BL21-STAR E. coli using a Ni-NTA column (Qiagen) followed by an anion-exchange
chromatography (HiTrapQ, GE Healthcare). Pure α-Syn monomers were obtained by
SEC (Superose 12 10/30, GE Healthcare) immediately prior to use. The purity of α-Syn
monomers (>98%) was determined by SDS-PAGE and quantified by densitometry
(ImageJ, NIH). Crude α-Syn aggregates/oligomers were generated by incubating
monomeric α-Syn (3 mg/mL) in PBS (20 mM NaPO4 pH 7.4, 140 mM NaCl) at 37 °C for
7 h. After oligomerization, the oligomers were separated from the remaining monomers
by SEC (Superose 12, GE Healthcare) and verified A11+ by dot blot.

Huntingtin protein
GST-tagged huntingtin exon 1 constructs with a 53 polyglutamine repeat (GST-Htt-53Q)
and a 20 polyglutamine repeat (GST-Htt-20Q). Protein was expressed and purified from
BL21-STAR E. coli as described85. Briefly, the GST-fusion protein was cleaved with
PreScission Protease (GE Healthcare) at 4 °C according to manufacturer protocol. The
free Htt-53Q proteins were further purified by SEC (Superose 12 10/30, GE Healthcare)
to obtain a monomeric population immediately prior to oligomerization. The purity of Htt53Q monomers (>95%) was analyzed with SDS-PAGE quantified by densitometry
(ImageJ, NIH). Oligomers were generated by incubating monomeric Htt-53Q (1 mg/mL)
at 37 °C for 1 h. Due to the rapid formation of Htt-53Q oligomers, monomeric Htt-20Q
(which oligomerized at a much slower rate) was used for the monomer assay in Fig. 1b.
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Crude aggregate fractionation
Insoluble aggregates were removed from crude aggregate preparations by centrifugation
at 10,000×g for 10 min. The supernatant containing soluble oligomers was transferred to
a fresh Eppendorf tube and the remaining pellet was gently resuspended in PBS. The
pellet fraction was centrifuged twice more before final resuspension at 1 mg/mL in PBS.
The fibrillar nature of the insoluble fraction was confirmed by Thioflavin-T (Sigma)
fluorescence in comparison to monomer preparation controls as described below.

SDS-PAGE and Native-PAGE
Proteins were separated by SDS-PAGE using NuPAGE™ 4–12% Bis-Tris protein gels
(Invitrogen), or separated by Native-PAGE using Novex™ 10–20% Tris-glycine or
NuPAGE™ 3–8% Tris–acetate protein gels (Invitrogen), as indicated. Total protein was
visualized with Coomassie stain (Simply Blue Safe Stain, Novex) or silver stain (Pierce
Silver Stain kit, Thermo Scientific) as indicated according to manufacturer instructions.
Immunoblots were performed as described below. Native-PAGE in-gel 26S proteasome
activity assay was performed using NuPAGE™ 3–8% Tris–Acetate gels (Invitrogen).
Samples were mixed with Novex™ Tris-glycine native sample buffer (×2) (Invitrogen) just
before loading. Electrophoresis was carried out in Novex™ Tris-glycine native running
buffer (Invitrogen) (with 0.5 mM DTT, 1 mM ATP, and 5 mM MgCl2) at 4 °C and 150 V for
4 h. Native gels containing 26S proteasomes were incubated with reaction buffer (50 mM
Tris pH 7.5, 10 mM MgCl2, 2 mM ATP, 1 mM DTT, 50 μM suc-LLVY-AMC) for 30 min at
37 °C. Fluorescent bands around proteasomes were visualized by standard gel-imaging
systems for DNA staining by ethidium bromide.
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Immunoblotting
For Native-PAGE western blots, proteins were transferred to nitrocellulose membrane
(GE) using Tris-glycine transfer buffer (Novex). Primary antibodies were purchased from
Invitrogen (anti-oligomer A11, and anti-Aβ N-terminus clone NAB228) and diluted 1:1000
in TBST +5% nonfat milk prior to use. AlexaFluor-647 conjugated secondary antibodies
(Invitrogen) were diluted 1:3500 in TBST prior to use. Membranes were blocked for 1 h at
room temperature in TBST +10% nonfat milk, briefly washed with TBST, incubated with
primary antibody for 1 h at room temperature, washed with TBST (3 × 5 min), incubated
with secondary antibody for 1 h at room temperature, washed (3 × 5 min), and imaged on
a Molecular Dynamics Typhoon 9410 Variable Mode Imager. Dot blots were performed
by spotting protein on 0.1 μM nitrocellulose membranes and processed the same as
Western blots.

Antibody neutralization assays
Anti-oligomer A11 (Invitrogen) and Aβ N-terminal antibody (clone NAB228, Invitrogen)
were buffer exchanged to 50 mM Tris (pH 7.4) with Zeba spin desalting columns (Thermo
Scientific). The antibodies (0.5 μg) were incubated with Aβ*56 (50 μM) or control buffer
for 25 min at 37 °C before adding to proteasome activity assays.

Crosslinking Aβ*56 and 20S proteasomes
Mammalian 20S proteasomes were buffer exchanged to 10 mM NaPO4 (pH 7 with Zeba
spin desalting columns (Thermo Scientific) and incubated with Aβ*56 oligomers (or an
equal volume of control buffer) for 45 min at 37 °C. One millimolar glutaraldehyde was
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added to the proteins, gently mixed, and incubated for 5 min at 37 °C. Crosslinking
reactions were quenched by the additional 1 M Tris–HCl pH 8 (1 mM). Proteins were
separated by SDS-PAGE and Native-PAGE and visualized with silver stain or
immunoblotting as described above.

Oligomer characterization
For atomic force microcopy imaging, preformed Aβ-iO were deposited on freshly cleaved
mica (Ted Pella Inc., Redding, CA) and allowed to sit for 30 s. The mica substrate was
then washed with 200 μL of ultrapure water and dried with a gentle stream of nitrogen.
Samples were imaged in tapping mode via ex situ AFM using a Nanoscope V MultiMode
scanning probe microscope (Veeco, Santa Barbara, CA). AFM images were analyzed
with Matlab equipped with the image processing toolbox (Mathworks, Natick, MA). For
negative stain electron microscopy, 6 μl of preformed Aβ*56 oligomers were applied to
ultra-thin copper 400 mesh carbon grids (Electron Microscopy Sciences) and imaged on
a JEOL JEM-2100 TEM.

Thioflavin-T florescence measurement
ThT (Sigma) was dissolved (1 mM) in PBS, filtered through a 0.2 μM syringe, and stored
at −20 °C until use. For the assays, 3 μg of Aβ was incubated at room temperature for
10 min in 100 μM of PBS with 20 μM ThT and fluorescence was measured (ex/em:
450/490 nm) in a Synergy2 plate reader (GenTek).
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Statistical analysis
The data were analyzed using an unpaired Student’s t-test (Prism). For all statistical
analyses, a value of p < 0.05 was considered significant.

Data availability
The authors declare that the data supporting the findings of this study are available within
the paper and its supplementary information files and are available from the
corresponding author upon request.
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Supplementary Figures

Corresponds to Figure 1B.
Supplementary Figure 1. A11(+) soluble aggregates of Aβ, α-Syn, and Htt-53Q impair the mammalian
20S proteasome in a concentration-dependent manner. Mammalian 20S proteasomes were incubated with
soluble aggregates of Aβ (A), α-Syn (B), or Htt-53Q (C) at the indicated concentrations and proteasome
activity (LLVY-amc hydrolysis) was measured. Aβ mixed aggregates are the same as used in Figure 1A.
Soluble oligomers from α-Syn and Htt-53Q are from Figure 1B. Half-maximal inhibition of the 20S is
indicated. The concentrations of aggregates are calculated based on the respective monomeric
peptide/protein mass (Aβ, 4.5 kDa; α-Syn, 14 kDa; and Htt-53Q, 22 kDa). All controls contained an equal
volume of buffer identical to that of the respective aggregates. Data is representative of three independent
experiments performed in triplicate. Error bars represent ± standard deviation.
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Corresponds to Figure 1B.
Supplementary Figure 2. A11(+) oligomers from Aβ, α‐Syn, and Htt‐53Q impair substrates that are specific for
all three proteolytic sites in the mammalian 20S proteasome. Mammalian 20S proteasomes were incubated
with Aβ oligomers (2µM) (A), α‐Syn A11+ oligomers (1µM) (B), or Htt‐53Q A11+ oligomers (0.1µM) (C), and
proteasome chymotrypsin‐like (LLVY‐amc hydrolysis), caspase‐like (nLPnLD‐amc hydrolysis), and trypsin‐like
(RLR‐amc hydrolysis) activity was measured. Chymotrypsin‐like and caspase‐like activity assays used 0.5nM of
20S proteasome, trypsin‐like activity assays used 1nM of 20S proteasome. The concentrations of aggregates
are calculated based on the respective monomeric peptide/protein mass (Aβ, 4.5 kDa; α‐Syn, 14 kDa; and Htt‐
53Q, 22 kDa). All controls contained an equal volume of buffer identical to that of the respective aggregates.
Data is representative of three independent experiments performed in triplicate. Error bars represent ±
standard deviation.
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Corresponds to Figure 1C.
Supplementary Figure 3. A11(+) A intermediate oligomers (A-iO) impair the degradation of
substrates specific for each of the three peptidase activities in the 20S, and A11(-) A protofibrils (APF) do not have any effect. Mammalian 20S proteasomes were incubated with peak A fractions from
size exclusion chromatography in Fig. 1D: 2.5M A-iO (A) or 5M A-PF (B). Chymotrypsin-like (LLVYamc hydrolysis, rfu/min) and caspase-like (nLPnLD-amc hydrolysis, rfu/min) activity assays used 0.5nM
of 20S proteasome, trypsin-like (RLR-amc hydrolysis, rfu/min) activity assays used 2nM of 20S
proteasome. The concentrations of aggregates are calculated based on the monomeric peptide mass
(4.5 kDa). All controls contained an equal volume of buffer identical to that of the respective aggregates.
Data is representative of three independent experiments performed in triplicate. Error bars represent ±
standard deviation.
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Corresponds to Figure 1C.
Supplementary Figure 4. Soluble high molecular weight A oligomers also impair the 20S
proteasome if they are A11 positive. (A) High molecular weight A11(+) oligomers of A were separated
by size exclusion chromatography, peak fractions (10l) were separated by native-PAGE and
coomassie stained (top). Each fraction (2l) was evaluated by slot blot for A11 immunoreactivity
(bottom). (B) 20S proteasome activity (nLPnLD-amc hydrolysis, rfu/min) was determined with fractions
from part A (0.5l). The concentrations of aggregates are calculated based on the monomeric peptide
mass (4.5 kDa). All controls contained an equal volume of buffer identical to that of the respective
aggregates. Data is representative of three independent experiments performed in triplicate. Error
bars represent ± standard deviation.
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Corresponds to Figure 1C.
Supplementary Figure 5. A11(+) A protofibrils impair the mammalian 20S proteasome. (A) A11(+) A protofibril
preparation was separated by size exclusion chromatography (Superose 6 GL). The protofibrils eluted in the column
void volume, indicating the soluble aggregates are >700 kDa (top). Equal volumes of each fraction were probed for
A11 reactivity (bottom). (B) Mammalian proteasomes were incubated with A11(+) A protofibrils (2.5M) and the
activity of all three active sites was measured by fluorescent substrate hydrolysis. The concentrations of aggregates
are calculated based on the monomeric peptide mass (4.5 kDa). All controls contained an equal volume of buffer
identical to that of the respective aggregates. Data is representative of three independent experiments performed
in triplicate. Error bars represent ± standard deviation. * = p < 0.05.
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Corresponds to Figure 1E.
Supplementary Figure 6. Incubation with antibody
targeted to the A N-terminus (1-8) does not rescue
proteasome activity. A intermediate oligomers (A-iO)
from Fig. 1D were incubated with buffer or monoclonal
antibody (NAB228, Invitrogen, epitope 1-8 A peptide) for
30 minutes at 37°C and tested for effect on proteasome

Corresponds to Figure 3A
Supplementary Figure 7. A*56 oligomers bind to the 20S proteasome. (A) 20S
proteasomes (0.4g) and A*56 oligomers (1.5g) (from Figure 3A) were
incubated separately or together for 30 minutes (37°C), were lightly crosslinked
for 5min, and then separated by SDS-PAGE (4-12% bis-tris gel). Total protein was
detected by silver stain. Lane 2 shows 20S proteasome migration pattern without
crosslinking for comparison. Lane 3 brackets denote intra-proteasome
crosslinked subunits after glutaraldehyde treatment (top bracket) and individual
subunits that did not crosslink (bottom bracket). The lack of aggregated protein in
the stacking gel (*) indicating minimal crosslinking conditions.

Corresponds to Figure 3.
Supplementary Figure 8. Substrate saturation curve on the WT 20S proteasome with and without A*56
oligomers. Mammalian 20S proteasomes (0.5nM) were assayed for nLPnLD-amc hydrolysis activity with
and without A*56 oligomers (1.2M) for 60 minutes at various substrate concentrations. The rate of amchydrolysis was plotted and fit using non-linear regression and the Michaelis-Menten equation (GraphPad).
Vmax and Km values are shown to the right. Experiment was performed in triplicate.

104

Corresponds to Figure 3B-D.
Supplementaary Figure 9. WT and 3ΔN proteasome preparations have expected activities. (A)
Chymotrypsin-like activity (LLVY-amc hydrolysis) is abolished in both wild-type 20S and 3ΔN 20S mutant
proteasomes after pre-treatment with proteasome inhibitor MG132 (50M). (B) Wild type 20S
proteasomes (1.4 nM) show gate opening by addition of a known gate-opening peptide, Rpt5 (300M).
However, as expected the Rpt5 peptide could not stimulate the open-gate mutant 3ΔN 20S proteasomes
(0.14 nM). Note there is 10X more WT 20S than 3ΔN 20S. Data is representative of three independent
experiments performed in triplicate. Error bars represent ± standard deviation.

Corresponds to Figure 6A.
Supplementary figure 10. The measured amc hydrolysis from 26S proteasome preparation is due to
single and double capped 26S activity and not 20S activity. Native-PAGE of 1g of mammalian rabbit
muscle 26S proteasome. In-gel enzyme activity assay (LLVY-amc hydrolysis) (left), silver stain (right).
Gel is representative of three 26S proteasome preparations from rabbit muscle. Note that the LLVYamc activity is only detectable from the 20S-19S complexes in these experiments.

105

Study 2: Hyperactivation of the proteasome in
Caenorhabditis elegans protects against proteotoxic stress
and extends lifespan
Raymond T. Anderson, Thomas A. Bradley, David M. Smith*
Journal of Biological Chemistry (2022)
DOI: https://doi.org/10.1016/j.jbc.2022.102415.

Department of Biochemistry, West Virginia University School of Medicine, 64 Medical
Center Dr., Morgantown, WV 26506
Corresponding: * David M. Smith
Email: dmsmith@hsc.wvu.edu

Keywords: Caenorhabditis elegans (C. elegans); Enzyme kinetics; Oxidative stress;
Proteotoxic stress; Proteasome; Protein degradation; Ubiquitin; Toxicity; Aging

Financial Support:
Some strains were provided by the CGC, which is funded by NIH Office of Research
Infrastructure Programs (P40 OD010440). This work was supported by NIHR01AG064188 to D.M.S. and NIH-F31AG058473 to R.T.A.
The Content is solely the responsibility of the authors and does not necessarily
represent the official views of the NIH

This article is licensed under a Creative Commons Attribution 4.0 International License:
https://creativecommons.org/licenses/by/4.0/. Modified with minor text edits.

106

ABSTRACT
Virtually all age-related neurodegenerative diseases (NDs) can be characterized by the
accumulation of proteins inside and outside the cell that are thought to significantly
contribute to disease pathogenesis. One of the cell’s primary systems for the degradation
of misfolded/damaged proteins is the Ubiquitin Proteasome System (UPS), and its
impairment is implicated in essentially all NDs. Thus, upregulating this system to combat
NDs has garnered a great deal of interest in recent years. Various animal models have
focused on stimulating 26S activity and increasing 20S proteasome levels, but thus far,
none have targeted intrinsic activation of the 20S proteasome itself. Therefore, we
constructed an animal model that endogenously expresses a hyperactive, open-gate
proteasome in Caenorhabditis elegans (C. elegans). The gate-destabilizing mutation
introduced into the nematode germline yielded a viable nematode population with
enhanced proteasomal activity, including peptide, unstructured protein, and ubiquitindependent degradation activities. These nematodes showed a significantly increased
lifespan and substantial resistance to oxidative and proteotoxic stress but significant
decrease in fecundity. The results show that introducing a constitutively active
proteasome into a multicellular organism is feasible and suggests targeting the
proteasome gating mechanism as a valid approach for future age-related disease
research efforts in mammals.
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INTRODUCTION
Aging is a biological process that happens in all multicellular organisms over time and is
characterized by the chronological accumulation of cellular damage leading to functional
decline as an organism grows older. Functional decline may be caused by many
coinciding systemic, cellular, and molecular factors, but one specific inevitability that
afflicts humans as we age is the disruption of cellular proteostasis leading to the buildup
of damaged and aggregate prone proteins1–3. The buildup of such non-native proteins is
an important hallmark of aging thought to contribute to organismal decline and has been
linked to several age-related diseases1,3–5. Two systems exist in the cell that are
responsible for degrading misfolded and damaged proteins: the ubiquitin proteasome
system (UPS) and the lysosome (autophagy). The UPS is highly regulated and is
responsible for degrading individual misfolded, damaged, or unneeded proteins, while the
lysosome is responsible for degrading larger cargo including organelles and large protein
aggregates. Many age-related diseases, including virtually all neurodegenerative
diseases (NDs), can be characterized by protein misfolding and accumulation, and in
many cases, these diseases have also been shown to have decreased UPS and
autophagic functions6–13. The definitive cause of decreased proteasome function has yet
to be determined. However, proteasome activity has been shown to decrease with age,
which could lead to protein accumulation, especially later in life when NDs primarily occur;
a wide range of literature supports this hypothesis14–23. In agreement with this notion,
synthetic proteasome impairment alone in mice and rats has been shown to cause
pathologies and symptoms associated with NDs24–28. To better understand the potential
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mechanisms of proteasome impairment in disease, understanding how the proteasome
regulates substrate degradation is needed.

The 20S proteasome, the proteolytic component, is a barrel like structure with four
stacked heptameric rings (⍺7, β7, β7, ⍺7)29. The ⍺-rings’ N-termini form “gates” that deter
non-specific degradation by interacting with one another to form a folded structure over
the central pore preventing unregulated substrate entry30. The gate’s structural stability is
mediated by the evolutionarily conserved YDR motif (Tyr-Asp-Arg[Ser]), which stabilizes
both the closed and open states of the 20S substrate gate29–33. The β-rings house two
copies of three distinct proteolytic sites that cleave after: Hydrophobic (chymotrypsin-like),
basic (trypsin-like), and acidic (caspase-like) residues. Several different regulatory caps
that bind to the 20S proteasome exist in the cell to aid in regulating protein degradation
by the proteasome (i.e., PA200/Blm10, PA28αβ, PA28γ, 19S), and many of these caps
have been extensively characterized34–38. The 19S regulatory particle is one of the
primary regulatory caps in the cytosol. It binds to one or both ends of the 20S proteasome
creating the 26S proteasome. The 19S consists of a base and lid region. The base
consists of a hexameric ring of AAA-ATPases for protein unfolding, and the lid contains
ubiquitin receptors and deubiquitinases for targeting substrates for degradation39–42. The
C-termini of the ATPase subunits contain a HbYX (hydrophobic, tyrosine, most amino
acids) motif, which docks into intersubunit pockets in the 20S complex causing
conformational changes in the 20S α-subunits triggering gate-opening43.
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Many previous studies have reported that one cause of proteasomal inhibition in aging
and disease states is the presence of oligomeric proteins and other types of protein
aggregates10,44–48. Our lab has recently shown that conformationally specific oligomeric
forms of misfolded neurodegenerative disease associated proteins (i.e., amyloid-β, αsynuclein, and huntingtin) can bind to and inhibit 20S proteasome activity by stabilizing a
closed gate conformation even in the presence of the gate-opening HbYX motif

49

.

However, this inhibition can be reversed with saturating levels of HbYX motif peptides,
highlighting the potential therapeutic opportunity in targeting the proteasomal gating
mechanism49.

Recent studies have targeted proteasome activation or upregulation as a type of therapy
to combat neurodegenerative disease or increase resistance to cellular stress50–54. In fact,
recent findings have shown that some FDA approved drugs can alter post-translation
modifications on the 26S proteasome that modulate its activity52. Other studies have
shown that overexpression of the 20S β5 subunit increases total proteasome levels
resulting in an increase in lifespan and resistance to cellular and organismal stressors55–
57

. While this demonstrates the protective effects of increasing proteasome amounts, we

sought to stimulate the intrinsic activity of endogenous 20S proteasomes. A previous
study in yeast has shown that an eleven-residue truncation of the ⍺3’s N-terminus creates
a 20S with a constitutively open proteasomal gate, which leads to dramatically increased
20S peptide hydrolysis30. More recently, it was shown that the expression of this
proteasome construct in the mammalian HEK293 cell-line leads to resistance to
proteotoxic stress induced by tau overexpression58. It is important to note that the
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truncation of α3 in HEK293 cells was exogenously overexpressed on a wild type α3
subunit background58. It was reported that the modified α3 incorporated into the 20S
proteasome well, but there still may be a small population of WT proteasomes present.
Thus far, no animal model has ever been made with a similar gate-opening mutation.
Creating this mutant in a multicellular organism poses many potential issues as regulated
protein degradation by the proteasome is imperative for almost every cellular process
including immune response, signal transduction, development, metabolism, and
progression through the cell cycle59–61. To this point, Bajorek et. al. showed that
expression of this open-gate proteasome in yeast hindered exit from stationary phase
thereby reducing population growth following nutrient deprivation. However, in the
logarithmic phase, where nutrients are readily available, population growth and cell
division appear normal

62

. In the present study, we generated the very first multicellular

organism, Caenorhabditis elegans, that expresses an endogenous open-gate
proteasome through direct genome editing. We examine how this hyperactive
proteasome affects C. elegans biology and impacts its lifespan, and resistance to
oxidative and proteotoxic stresses.

RESULTS and DISCUSSION
Mutation Design
The 7 α-subunits of the eukaryotic proteasome contain N-terminal regions that fold over
the central pore closing it off to prevent unregulated substrate entry. The N-terminus of
each α-subunit, while highly conserved, differs slightly in sequence, length, and structure,
and therefore, plays a unique role in regulating gate closure. The N-terminus of α3 is
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uniquely important for gating in that it extends across the length of the entry pore acting
as an anchor by providing hydrogen bonding between the other α-subunit N-termini
resulting in a stable closed gate conformation29(Fig. 1A). Given the high sequence
conservation of the α3 N-terminus among eukaryotes (Fig. 1B), we hypothesized that
making this mutation in nematodes would also induce gate opening and stimulate
proteasome activity as has been shown in yeast and mammalian cells30,58. Using CoCRISPR Cas9 technology with the assistance of InVivo Biosystems (Oregon, USA), we
were able to directly edit the genome of C. elegans to generate a nematode population
with endogenous expression of a hyperactive, open-gate proteasome.

Figure 1. Generation of C. elegans with open-gate 20S proteasome.
A. Top view of S. cerevisiae 20S (1RYP) α-ring with α3 subunit in blue and its N-terminal gating residues that
were removed by gene editing illustrated in red and cut site marked with a black “X”.
B. 20S α3 N-terminal sequence alignment of C. elegans, H. sapiens, and S. cerevisiae showing homology,
the YDR/S motif demarcated between the red lines. Specific residues deleted to form an open-gate a3DN20S in each species is indicated by the dashed line (References 30 and 58)
C. SDS-PAGE western blot probing for 20S α-subunits (Anti-Proteasome α’s1,2,3,5,6,7; MCP231)) using αtubulin (anti-Tubulin YOL1/34, ab6161) as a loading control (N=3, P<0.05). Values given are the average
relative proteasome abundance in each strain relative to tubulin ± SD.
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Two identical mutant clones were generated separately to control for off-target editing
resulting in the strains: COP1857 pas-3(knu746 [NTD del]) and COP1858 pas-3(knu747
[NTD del]), which we will refer to as α3ΔN throughout this study. In these mutants, 36
base pairs were deleted and replaced with 12 base pairs of new coding (for PCR
Genotyping) resulting in an 8 residue N-terminal deletion of the α3 subunit including the
YDR motif (Fig. S1A and B). Whole genome sequencing on both strains confirmed a
successful α3 N-terminal truncation, and a bioinformatic analysis confirmed no editing in
off-target regions for both clones (Fig. S1C). As determined by western blot, Native-PAGE
showed proper assembly of the α3ΔN 20S (Fig. S2A), and SDS-PAGE showed no
detectible difference in expression compared to WT (Fig. 1C, S2B and C). Unchanged
proteasome levels is important to note as any differences in proteasome activity detected
is not due to major changes in expression but to the activity of the proteasome itself.

Proteasome Activity
After confirming the successful α3 N-terminal truncation and unchanged expression
levels, we sought to determine whether this mutation did, in fact, cause increased
proteasome activity in α3ΔN compared to WT. 20S activity can be measured in-vitro using
small fluorogenic peptides conjugated to 7-amino-4-methylcoumarin (AMC) which
becomes fluorescent following cleavage from specific 3-4 amino acid peptides. Therefore,
activity can be measured by determining the rate of increased fluorescence over time.
Gate opening, rather than active site activation, can be validated by determining the
stimulation of activity at all three of the 20S’s β catalytic sites using Suc-LLVY-AMC
(chymotrypsin-like), Z-LLE-AMC (caspase-like), and Boc-LRR-AMC (trypsin-like). Using
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the highly proteasome specific substrate, Suc-LLVY-AMC, and the proteasome inhibitor,
MG132, to normalize to proteasome-specific proteolysis, we observed a 13-fold increase
in 20S activity in α3ΔN lysates compared to WT (Fig. 2A). Z-LLE-AMC and Boc-LRRAMC were also hydrolyzed faster by α3ΔN as expected for an open-gate proteasome
(Fig. 2A and B). In fact, α3ΔN lysates were as much as 50Xs more active than WT (WT
was 98% less active for Boc-LRR-AMC) indicating extensive increase in proteasomal
peptidase activity. Moreover, this result demonstrates that all three of these peptides are
relatively specific for the proteasome in C. elegans lysates, since the 20S mutation
substantially increased peptide hydrolysis as expected, and the activity reported was
sensitive to the proteasome inhibitor MG132.

To directly confirm the increased activity was due to proteasome activation specifically,
we performed an in-gel activity assay which shows proteasome peptidase activity after
separating the lysate via Native-PAGE. Both α3ΔN clones showed drastically higher 20S
signal compared to WT, which was hardly detectable (Fig. 2C). The 26S peptide
hydrolysis activity was also elevated in the α3ΔN clones relative to WT after normalizing
to 26S protein levels observed via immunoblot (Fig. 2C). After the addition of 0.02% SDS,
which induces gate opening in the WT 20S43,63,64, we observed an equalization of the
signal between WT and α3ΔN 20S, further implicating gate opening as the primary means
of activation in these mutants (Fig. 2C; Fig. S3). We also observed a light band above the
20S likely corresponding to a PA200-20S complex, a proteasomal activator that has been
reported to bind more readily to open-gate proteasomes65.
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To determine the extent to which α3ΔN in C. elegans opens the 20S gate, we examined
the activation capacity of the 26S proteasome. Typically, the 26S proteasome can be
activated by 4 to 5-fold in the presence of ATP 31, which induces gate opening. When we
added ATP to WT or α3ΔN lysates, we found that it stimulated Suc-LLVY-AMC peptide
substrate entry by 5.5-fold for WT and 2.3-fold for α3ΔN lysates suggesting that the
mutation may not cause completely stable gate opening in these proteasomes since the
α3ΔN 26S can become more active when saturated with ATP (Fig. 2D; Fig. S4). In
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Figure 2. The nematode α3ΔN proteasome is hyperactivated in vitro. All activity assays were performed
using nematode lysates from synchronized young-adult populations. All quantitative data shown are normalized
to MG132 inhibition.
A. Raw kinetic data of Suc-LLVY-AMC hydrolysis by lysates prepared using 20S lysis buffer. Fluorescence
(ex/em: 380/460 nm) was measured every 60sec for 2hrs (1hr shown). Values shown are average
relative fluorescence units (RFUs) at each timepoint ± SD normalized to MG132 inhibition (N=3).
B. Quantified peptidase activity using fluorogenic substrates targeted to all three proteasomal active sites:
chymotrypsin-like (Suc-LLVY-AMC), caspase-like (ac-LLE-AMC), trypsin-like (Boc-LRR-AMC). Data is
shown as % of mean α3ΔN activity ± SD normalized to MG132 inhibition (N=3).
C. Native-PAGE (4-8% Tris-acetate gel) of lysates from Day 1 adults showing in-gel peptidase activity after
incubation with 50µM Suc-LLVY-AMC in 26S activity buffer (includes ATP) (Left), peptidase activity after
incubation with 0.02% SDS to induce gate opening (Middle) and immunoblot for 20S α-subunits (AntiProteasome α’s1,2,3,5,6,7; MCP231) (Right). Experiments were performed in triplicate and images
shown include 1 replicate of each strain (WT, α3ΔN1, α3ΔN2). Arrows indicate PA200-20S band.
D. Quantified peptidase activity (Suc-LLVY-AMC hydrolysis, rfu/min) using lysates with and without
ATP. Values shown are average degradation rate ± SD normalized to MG132 inhibition (N=3).
Unnormalized data shown in Fig. S4.
E. Fluorescence polarization (FP) of FITC-Casein over 4hrs using 5ug lysate from each strain in the
presence of ATP(100µM MG132 used to inhibit proteasome activity). Values are the 2nd order
smoothing of the raw FP at each timepoint (N=3).
F. Total change in FP (ΔmP) of FITC-Casein after 4hrs. Values represent the average ΔmP ± SD after
normalizing to MG132 inhibition (N=3).
G. Exponential decay curve of ub4(lin)-GFP-35 degradation with half-life (t1/2) and R2 value labeled for
each curve, normalized to MG132 inhibited. Unnormalized data shown in Fig. S4. (N=3)
All experiments were performed in triplicate at least twice and error bars represent ± SD; **p≤0.01,
***p≤0.001, ****p≤0.0001.

agreement, prior studies using the mammalian open-gate 20S also show the 19S bound
α3ΔN can reach a higher level of “full” activation compared to 19S bound to WT 20S
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The observation that mutant lysates can be further stimulated by ATP suggests that α3ΔN
proteasomes may still offer a level of regulation that may contribute to the viability of these
mutant populations. It is possible that a completely open gate would be lethal in a
multicellular organism given the crucial role of proteasomal regulation during
development (see below for more). Another open-gate mutant has been generated in
yeast with a truncation in both the α3 and α7 N-termini (α3α7ΔN) resulting in more
extensive activation than α3 truncation alone 62. We attempted to introduce this construct
in C. elegans and were only able to produce heterozygous populations suggesting
homozygosity is lethal. This observation is consistent with the hypothesis, that our α3ΔN
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20S mutant is not fully open, which may contribute to the successful generation of this
organism.

Thus far, we have shown 20S activity in vitro using only small fluorogenic peptides, which
is useful because it provides information about degradative capacity and the degree to
which α3ΔN elicits gate opening. However, it does not necessarily provide direct evidence
α3ΔN 20S’s ability to degrade more physiologically relevant substrates such as
intrinsically disordered proteins (IDPs) and polyubiquitinated proteins. Protein
degradation increases the mobility of fluorescently labeled peptides which can be
measured with fluorescence polarization (FP) by assessing the rotational rates of the
fluorophore. We used FP to monitor degradation of the of the unstructured fluorescein
isothiocyanate labeled casein (FITC-casein). With ATP, we observed a 4-fold higher
change in FP in α3ΔN compared to that of WT (Fig. 2E and 2F) demonstrating an
increased capacity of α3ΔN lysates to degrade IDPs (i.e. casein) under physiologic
conditions. When the identical experiment was repeated without ATP, FITC-casein
degradation was undetectable in WT, while degradation was clearly visible in α3ΔN (Fig.
S4B) demonstrating that the free α3ΔN 20S (ATP-independent activity) has increased
IDP degradative capacity as expected. While enhanced degradation of unfolded
substrates is expected with a more open proteasome gate, it is not expected that α3ΔN
proteasome would stimulate degradation of folded substrates since folded domains must
be unfolded by 19S ATPases before entering the 20S, which is known to be rate limiting.
To assess ubiquitin-dependent (Ub-dependent) degradation capacity, we used ub4(lin)GFP-35, which contains an N-terminal linear tetra-ubiquitin chain fused to a circularly
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permuted GFP with a 35-residue unstructured initiation site on its C-terminus

42

.

Surprisingly, the α3ΔN lysates unfolded and degraded this substrate nearly twice as fast
as the WT lysates (Fig. 2G and S4C). In agreement with these findings, open-gate 20S
expression in mammalian cells (in a WT proteasome background) also showed enhanced
Ub-dependent degradation of a protein substrate58. These combined findings in two very
different systems provide compelling evidence that gate-opening can enhance Ubdependent protein degradation. While the mechanism behind this observation is not
understood, perhaps enhanced substrate entry into the 20S during initial unfolding events
contributes, as previously suggested 58.

Lifespan and Other notable phenotypes
After confirming the viability and proteasome activation in α3ΔN, we sought to
characterize their phenotypic differences relative to WT. As mentioned previously, a wide
range of literature reports that proteasome activity declines with age in many model
systems
66

14–23

, and its inhibition leads to a dramatically decreased lifespan in C. elegans

. In addition, many long-lived nematode mutants are characterized by increased

proteostasis
activity

68,69

67

which has been linked in some (i.e., dnj-21 and glp-1) to increased UPS

. Thus, we asked if hyperactivation of the proteasome core particle could

impact lifespan. Visualized using a Kaplan-Meier curve, we found that open-gate mutants
have a median lifespan of 20 days compared to 17 days for WT nematodes corresponding
to a 20% lifespan extension for α3ΔN (Fig. 3A, P<0.0001). This is consistent with previous
studies where proteasome upregulation increases cellular viability in mammalian systems
70

and extends the lifespans of C. elegans and D. melanogaster

56,57

. However, the
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mechanisms of activation studied in the context of C. elegans and D. melanogaster
lifespan extensions have relied on β5 subunit overexpression to increase total
proteasome levels, not activation of the proteasome itself. The data shown here confirms
that intrinsic proteasome activation via gate opening can also extend lifespan.

While open-gate proteasome expression resulted in no obvious physical abnormalities
and an increased lifespan, we did notice a slower population growth in α3ΔN. To
investigate this, we calculated the average number of viable offspring per nematode and
found a >90% decrease in fecundity for α3ΔN compared to WT (Fig. 3B). This contrasts
with a previous study showing that increased proteasome levels (20S and 26S) in C.
elegans elicited a 12% increase in fecundity

56

. This dichotomy demonstrates that

upregulation of proteasome amounts with fully intact gating residues is not physiologically
analogous to proteasome activation via gate-opening. Clearly, the loss of the ability to
close the proteasome gate has a negative impact on reproductive and/or developmental
systems; however, the disruptions are limited as some embryos do survive to adulthood.
This decrease in fecundity could potentially contribute to the increased lifespan seen in
α3ΔN as fertility and lifespan are typically inversely related 71.
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Figure 3. Lifespan extension in α3ΔN and other notable phenotypes.
A. Kaplan-Meier curve of survival for α3ΔN (N=139) and WT (N=121) (log-rank test, P<0.0001).
B. Average number of hatched progenies for each strain (N=4, P<0.0001).
C. Activity counts from wMicroTracker™ throughout larval development showing lethargus and peak activity
for each larval stage. Data represents a 2nd order smoothing of activity counts over 72hrs (N=12).
D. Average length measurements throughout development to day 8 of adulthood (N≥3) ± SD.
E. Daily consumption of OP50 E. coli (ΔOD600) following L1 arrest ± SD(N=12)
F. Pharyngeal pumping (pumps/min) during the first five days of adulthood (N=15).
The data are representative of two or more independent experiments. Error bars represent ± standard
deviation; **P≤0.01, ***P≤0.001, ****P≤0.0001.

Slower development is also associated with increased lifespan in many strains72 so we
sought to determine if α3ΔN’s developmental timeline was delayed. C. elegans pass
through four larval stages (L1-L4) before reaching adulthood, each of which consisting of
a “lethargus” period, where feeding and locomotion are transiently arrested during the
molting process

73

. Using a specially designed nematode wMicrotrackerTM (InVivo

Biosystems) to detect nematode activity levels in liquid culture, we found no significant
developmental timeline differences between α3ΔN and WT with both strains going
through their developmental “lethargus” periods synchronously and reaching adulthood
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within 50 hours (Fig. 3C). In addition to identical developmental progression, we also
found that the two strains remained the same length to each other and grew at the same
rate through each developmental stage measured, which further supports the consistent
developmental timeline. However, after reaching adulthood and throughout the gravid
period, α3ΔN remained consistently shorter in length than WT (Fig. 3D). The precise
reason for this in unclear but could be attributed to fewer eggs present in α3ΔN as
described above or a decreased cell size due to differences in overall food consumption.
We calculated E. coli (OP50) consumption rates by measuring daily changes in OD600
and found that α3ΔN consumed less than WT (Fig. 3E). We then measured pharyngeal
pumping (pumps/min) to determine if this correlated with α3ΔN’s decrease in overall food
consumption and found that α3ΔN had consistently lower pumping frequency compared
to WT over the first five days of adulthood (Fig. 3F). It is tempting to draw connections
between reduced caloric intake (potentially due to increased satiation or pharyngeal
pumping defects) and increased lifespan, as this is a constant theme in other studies and
model systems74, including humans. For example, mutations in eat-2 cause decreased
food consumption by directly decreasing pharyngeal pumping rates and thus food
consumption that leads to a significant increase in lifespan75,76. However, the pharyngeal
pumping rates are ~90% lower in the eat-2 mutants76 compared to WT, while the α3ΔN
pumping rates are only ~10% lower than WT (Fig. 3F). Therefore, it is unlikely that the
slight decrease in pharyngal pumping rates in the α3ΔN is causing a caloric restriction
phenotype. Nonetheless, the data presented here demonstrate that expression of an
open-gate proteasome in C. elegans is viable, increases lifespan, and the only “major”
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physiological deficiency found is decreased fecundity as the other phenotypic differences
shown here are relatively small, even though statistically significant.

Resistance to Paraquat
Paraquat is a potent herbicide, which produces reactive oxygen species in eukaryotes
through mitochondrial disruption77 and has been used in studies with eukaryotes including
C. elegans as a toxin induced Parkinson’s disease model78–80. In the context of
proteostasis, oxidative stress has been observed to cause the dissociation of 19S from
the 20S
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and several studies have shown that both the 20S54,81–84 and 26S85,86 are

responsible for the degradation of oxidatively damaged proteins. With this in mind, we
sought to determine whether our open-gate strain displayed resistance to paraquat. We
exposed our nematode population to 100mM paraquat on solid NGM agar and found that
after 25 hours, 75% of the α3ΔN population survived whereas only 30% of the WT
population survived (Fig. 4A). These results clearly demonstrate that this gate opening
mutation in C. elegans provides protection from the toxin. In addition, a native-PAGE
immunoblot for 20S and 26S after 20mM paraquat treatment showed that paraquat
reduced 26S levels in both WT and α3ΔN, but that the 20S levels only increased in the
WT (Fig 4B). This result further indicates a reduced physiological response to paraquat
in α3ΔN. Taken together, the resistance of α3ΔN to paraquat is consistent with previous
reports that showed oxidative stress resistance when proteasome amounts are
increased55–57 and adds to the field that intrinsic proteasome activation via proteasomal
gate-opening is also protective against the oxidative stress inducing toxin, paraquat.
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Figure 4. α3ΔN are resistant to paraquat and heat shock (HS).
A. Synchronized L4 nematodes exposed to 100mM paraquat on solid agar for 25hrs with survival counted
every hour (N=5). Values are mean survival ± SEM (N=5). The data shown are representative of two
independent experiments.
B. Native-PAGE immunoblot for 20S (Anti-Proteasome α’s1,2,3,5,6,7; MCP231) and 26S (AntiPSMD7/Mov34, ab140428) complexes with and without indicated paraquat treatment. The image
shown is representative of 2 independent experiments.
C. Young adult nematodes scored as dead or paralyzed 17hrs after a 2hr and 2.5hr 37˚C HS. Bar graphs
represent the average amount dead or paralyzed between 5 plates (20 nematodes each) ±SD;
**P≤0.01, ***P≤0.001, ****P≤0.0001.
D. Population (%) dead or paralyzed under each timepoint to visualize the cumulative outcome.
E. SDS-PAGE immunoblot showing polyubiquitin accumulation (anti-ubiquitin Ubi-1, ab7254) after HS with
actin (anti-βActin, AC026) as a loading control. FC (fold control) quantifies the ubiquitinated
proteins based on the respective control lane (N=2). Statistical significance was calculated using 2-way
ANOVA and P≤0.05 was considered statistically significant. Image shown is representative of 2
biological replicates. Additional details shown in Fig. S5. *P≤0.05.
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Resistance to Heat Shock
Elevated temperatures destabilize protein tertiary structure causing unfolding, protein
aggregation and a cellular heat shock (HS) response. The role of the proteasome in the
HS response in multicellular organisms is poorly understood. Although, recent evidence
suggests that the 26S proteasome becomes stably activated during HS87. Nevertheless,
given that α3ΔN expression during oxidative stress is protective, we sought to determine
whether its expression is also protective under heat induced stress. The HS was
performed by shifting synchronized young adults from 20˚C to 37˚C for 2hrs or 2.5hrs with
a 17hr recovery period followed by survival and paralysis scoring. After the 2-hour heat
shock, ~30% of the WT population was paralyzed while the mutant strain remained largely
unaffected (Fig 4C) (P<0.001). When combined with survival data (Fig. 4D), 36% of the
WT population was adversely affected by a 2-hour HS compared to only 2% of α3ΔN (Fig.
4C). Since 2-hours at 37˚C was not sufficient to cause significant death in either strain
(Fig. 4C, P<0.05), we increased the HS by 30 minutes and repeated the analysis. After
2.5hrs at 37˚C, α3ΔN paralysis increased slightly to ~5%, and paralysis of the WT
population remained similar to the 2hr exposure (Fig. 4C) (P=0.0017). The mortality rate,
however, was more significantly impacted; 50% WT population died compared to only
20% of the α3ΔN population (Fig. 4C) (P<0.0001). Taken together, the 2.5hr HS
adversely impacted 75% of the WT population but only 25% of the mutant population (Fig.
4D).

In addition to the phenotypic analysis, we also analyzed the accumulation of
polyubiquitinated proteins by western blot. We quantified the high-MW chain densities
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after 2 and 2.5hrs of HS at 37°C and normalized each strain to non-HS control.
Interestingly, HS increased the high-MW chains by 1.95-fold in the WT, but only 1.25-fold
in the α3ΔN at 2hrs. Likewise, the 2.5hr HS induced high-MW chains to 1.66-fold in the
WT, but only 1.30-fold in the α3ΔN (Fig. 4E). The two strains are statistically significantly
different at 2hrs (P=0.027), but these data did not reach significance at the 2.5hr timepoint
(P=0.177), though the trend was consistent (Fig. S5). The differences seen in
polyubiquitin chain accumulation suggests the open-gate strain may degrade
polyubiquitinated proteins more efficiently. This is consistent with observations seen in
mammalian cells where expression of α3ΔN in HEK293 cells showed enhanced ubiquitindependent degradation of transiently overexpressed Ub-GFP
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. It is also plausible that

heat induced unfolding could allow for ubiquitin independent degradation by the α3ΔN20S, preventing the need for polyubiquitination. The ubiquitin blots also showed
comparatively more monomeric ubiquitin present in α3ΔN after HS further indicating a
reduced amount of polyubiquitinated species in α3ΔN post HS.

CONCLUSION
In this study, we successfully generated a C. elegans animal model endogenously
expressing a hyperactive, open gate proteasome. Using CRISPR, we generated the open
gate proteasome by making an 8-residue deletion from the N-terminal gating region of
pas-3, which encodes the 20S α3 subunit. The mutation resulted in an open-gate
proteasome with at least a 13-fold increase in peptide substrate entry and had
substantially increased capacity to degrade unstructured and ubiquitinated proteins.
Increased degradation of both peptide and protein substrates is consistent with previous
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studies examining this mutant in yeast and mammalian cells30,58. The strain expressing
hyperactive proteasomes had a 20% increase in lifespan compared to WT and the adult
nematodes specifically had surprisingly few detrimental phenotypes. The most striking
phenotype appeared to be related to embryogenesis causing a substantial reduction in
fecundity. Our data also showed that the open gate strain is significantly more resistant
to oxidative stress and heat exposure compared to WT. This gate opening mutation also
resulted in reduced polyubiquitin accumulation after heat shock suggesting that the
α3ΔN-26S can degrade ubiquitinated proteins more efficiently than WT or that the α3ΔN20S is capable of degrading proteins that are misfolded by heat prior to ubiquitination. In
addition, our previous studies have also shown that this open channel proteasome mutant
is completely resistant to inhibition by some pathological oligomers that can be found in
various neurodegenerative diseases49. Future studies currently underway will seek to
verify this finding in nematodes in addition to analyzing global proteomic and mRNA
expression changes caused by proteasome hyperactivation. Together, the data
presented here have shown that expression of a hyperactive open-gate proteasome in a
simple multicellular organism is not only feasible but also increases lifespan and
resistance to proteotoxic stress. Therefore, these findings support the hypothesis that
activating proteasome function via gate opening could be a viable and useful approach
to increase proteostasis, and to potentially treat neurodegenerative diseases whereby
proteostasis and protein degradation are perturbed.
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METHODS
Strains and Maintenance.
Standard methods of culturing C. elegans were followed88. All strains were cultured at
20˚C on standard NGM plates seeded with OP50. Wild-type and CRISPR edited strains
used in this study were obtained from InVivo Biosystems (Oregon, USA). All strains used
include: N2, COP1857 pas-3(knu736 [NTD del]), and COP1858 pas-3(knu737 [NTD del]).
Most experiments were performed with both mutant clones and yielded similar results.
Data shown are primarily from COP1857 pas-3(knu736 [NTD del]). Age synchronization
was performed through alkaline bleaching discussed previously89. Well-fed gravid adults
from 2 10cm plates were collected and washed 3 times with ddH2O in 15mL conical tubes.
Water was aspirated to 3.5mL and 1.5mL freshly prepared bleach/NaOH mixture was
added [1mL 5% sodium hypochlorite (Fisher Scientific) and 0.5mL 5N NaOH. The
nematode/bleach solution was vortexed every 2 minutes for 10 minutes until no nematode
fragments remained. Sterile M9 was added to the solution to neutralize the reaction and
the tubes were centrifuged at 3,000xg for 1 minute to pellet the eggs. Eggs were washed
with 10mL sterile M9, centrifuged again for at 3,000xg for 1 minute, and M9 was
discarded. The pelleted eggs were added to fresh 15mL conical tubes containing 7.5mL
sterile M9 and incubated overnight with light agitation to allow for hatching. The resulting
L1 arrested nematodes were harvested within 24hrs, plated on E. coli (OP50) seeded
plates, and incubated in a 20˚C incubator until desired stage.
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CRISPR-Cas9 approach.
The CRISPR/Cas9 system was used with homology-directed repair (HDR) as described
previously90 to precisely delete amino acids 2-9 of pas-7. The strains produced are
COP1857 pas-3(knu736 [NTD del]), and COP1858 pas-3(knu737 [NTD del]). The strains
were made and provided by InVivo Biosystems (formerly NemaMetrix). Co-CRISPR: The
dpy-10 co-CRISPR method described previously 91 was used to identify animals in which
the CRISPR/Cas9 system was active. The injection strain used in DSMI01 was N2,
obtained from the C. elegans Genetics Center (CGC) (University of Minnesota,
Minneapolis). Single guide RNA sequences used include:
5’ sgRNA sequence: 5’ - TCGTTCTACTATCGTAACGA - 3’
3’ sgRNA sequence: 5’ - AACGACCATCTTCTCTCCGG - 3’

DNA extraction for PCR and off-target effects analysis.
Genomic DNA (gDNA) was extracted for whole genome sequencing (WGS) and
genotyping via PCR. For WGS, two 10cm plates of pas-3(knu746 [NTD del]) and pas3(knu747 [NTD del]) were collected and washed several times with M9 to remove residual
bacteria. Washed populations were resuspended in lysis buffer [1x High Fidelity (HF)
buffer (New England Biolabs) + 1mg/mL Proteinase K (Thermo Scientific)], frozen at 80˚C for 15 minutes, heated to 65˚C for 1hr for lysis and 90˚C for 20˚C to deactivated
proteinase K. Cellular debris were spun down at 16,000xg and the supernatant containing
gDNA was collected and sent to Psomagen (Rockville, Maryland, USA) for sequencing
and off target effect analysis against WT (Bristol N2) reference genome (WBcel235). For
PCR genotyping, a single nematode was lysed in 10µL lysis buffer as described above.
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PCR was performed in 10µl PCR buffer [OneTaq (NEB), 1µL gDNA, and .5µM of Forward
and Reverse Primers] with standard temperature parameters (see below). Products were
separated on 2% agarose gel containing ethidium bromide and imaged using Gel Doc XR
imaging System (Bio-Rad). WT PCR amplifications run at 331bp, while mutant PCR
bands run at 317bp. Primers and thermocycler conditions listed below.
Primers used:
‐

WT forward: gaATGACTATTTTTAGTCCGGAGGGA

‐

α3ΔN forward: TCGTTACGATAGTAGAACGACCATC

‐

Reverse (used for both strains): ATTCTGGACGAGCTGCTCAACT

Thermocycler conditions:
‐

Initial Denaturation: 98˚C

‐

Cycles (35x): 98˚C, 50˚C, 72˚C

‐

Final extension: 72˚C

‐

Hold: 4˚C

Protein extraction.
Protein lysates were extracted by collecting two 10cm plates of synchronized young
adults and washing several times with M9. The clean nematode pellets were then
resuspended in appropriate ice-cold lysis buffer depending on the application: 20S lysis
buffer: [50mM Tris-HCl pH.7.4, 1mM DTT, 5% Glycerol], 26S lysis buffer: [50mM Tris-HCl
pH 7.4, 1mM DTT, 10% glycerol, 2mM ATP, 5mM MgCl2]. Samples were then sonicated
using Sonic Dismembrator Model 100 (Fisher Scientific) at an output power of 1 (5 x 10
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pulses) until no nematode fragments were visible. Samples were then spun down at
16,000xg for 15min to pellet cellular debris. The supernatant was collected, and protein
concentration was determined using Coomassie Plus (Bradford) Protein Assay (Thermo
Scientific). Samples were either used immediately or stored at -80˚C for future use.

Proteasome activity assays – fluorogenic substrates.
20S and 26S Proteasome activity in C. elegans lysates (5µg) was measured using
fluorogenic peptides or protein substrates as described43,49 in 96-half-well non-binding
surface treated black plates (corning) at 20˚C. To measure 20S activity, lysates were
added to a reaction buffer containing 50 mM Tris–HCl (pH 7.4), 2mM DTT, and 100 μM
fluorogenic substrate (Suc-LLVY-AMC, ac-LLE-AMC, Boc-LRR-AMC). To measure 26S
activity, lysates were added to reaction buffer appropriate for ATP hydrolysis [50mM TrisHCl (pH 7.4), 100µM Suc-LLVY-AMC, 2mM DTT, 2mM ATP, and 5mM MgCl2].
Fluorescence was measured every 60S for 2hrs (ex/em: 380/460 nm). Activity was
calculated as the rate of increase in fluorescence intensity over time (rfu/min) ± SD (N=3).
Experiments were repeated at least twice.

Proteasome activity assay – protein substrates.
Unstructured protein degradation was measured in 50µl reactions using 96-half-well nonbinding surface treated black plates (Corning) at 20°C. C. elegans lysates (5µg) were
incubated in reaction buffer with ATP/MgCl2[50mM Tris-HCl pH 7.4, 1mM DTT, 5%
glycerol, 2mM ATP, 5mM MgCl2] or without ATP/MgCl2 [50mM Tris-HCl pH 7.4, 1mM
DTT, 5% glycerol] containing 0.8µg FITC-casein (Sigma). Fluorescence was measured
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every 2min for 4hrs using the Synergy 2 Microplate reader (BioTek). Fluorescence
polarization (FP) was calculated in Gen5 software version 2.0. Degradation rates were
determined by calculating the total change in FP over 4 hours. Ubiquitin dependent
degradation was assessed using a recombinantly expressed linear tetraubiquitin fused to
a circularly permuted GFP with a 35-residue unstructured region on its N-terminus
(Ub4(lin)-cpGFP-35) (gift from Andreas Matouschek) as described49. Degradation rate
was calculated by determining the half-life (t1/2) of GFP fluorescence using one phase
decay fit in GraphPad (Prism) (N=3). Experiments were performed at least twice.

In-gel proteasome activity assay and native western blot.
Native-PAGE in-gel 20S/26S proteasome activity assay was performed as described
previously49. Protein lysates (20µg) were mixed with NovexTM Tris-glycine Native Sample
Buffer (Invitrogen) and separated on NuPAGETM 3-8% Tris Acetate gels (Invitrogen) using
NovexTM Tris-glycine Native Running Buffer (Invitrogen) containing 1mM DTT, 2mM ATP,
and 5mM MgCl2 at 4˚C and 50V overnight. The gels were then incubated with slight
agitation in 26S activity buffer [50mM Tris-HCl pH 7.4, 2mM DTT, 5% glycerol, 2mM ATP,
5mM MgCl2, and 100µm Suc-LLVY-AMC] for 30min at 20˚C and visualized using ethidium
bromide imaging protocol on G:BOX XX9 (Syngene). Gate-opening was induced by
incubating in activity buffer + 0.02% SDS for 30min at 20˚C and imaged as described
above. To perform immunoblot, the gel was transferred to Immobilon®-FL PVDF
membrane at 30V overnight. The membrane was blocked in tris buffered saline + 0.01%
tween20 (TBST) +10% nonfat milk for 1hr at room temperature (~20˚C), briefly washed
and incubated with primary antibody (Anti-Proteasome α’s1,2,3,5,6,7 subunits, Enzo,
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MCP231; Anti-PSMD7/Mov34, ab140428) diluted 1:1000 in TBST+5% nonfat milk at 4˚C
overnight, washed (3 x 5min), washed with TBST (3 x 5min), incubated with secondary
antibody (DyLightTM 550, Thermo, 10173; Alexa Fluor Plus 680, A32729) diluted 1:3000
in TBST+ 5% nonfat milk for 1hr at room temperature, washed with TBST (3 x 5 minutes),
and imaged using Amersham Typhoon (GE). The image shown is representative of 3
biological replicates. Note regarding native western: We repeatedly saw less 20S signal
in the 26S band than typically expected. We speculate that in these native western
conditions may allow for some steric blocking of the 20S epitope in the C. elegans 26S
complex (e.g. Fig 2C), though other explanations are also possible.

Western blot – proteasome.
The antibody used to determine proteasome levels were purchased through Enzo (AntiProteasome α’s1,2,3,5,6,7; MCP231)). The antibody used to label the loading control,
tubulin, was purchased through abcam (anti-Tubulin YOL1/34, ab6161).”. The primary
antibodies were diluted 1:1000 in TBST + 3% bovine serum albumin (BSA). Secondary
antibodies were purchased through Invitrogen (DyLight™ 800, 10024; Alexa Fluor™ Plus
680, A32729) and diluted 1:3000. 100µg of lysate from each strain was separated on
NuPAGE™ Bis-Tris 4-12% (Invitrogen) gel and transferred to Immobilon-FL PVDF
membranes (Millipore). Membranes were blocked for 1hr at room temperature in
TBST+3% BSA, briefly rinsed with TBST, incubated with primary antibodies overnight at
4˚C, washed with TBST (3 x 5min), Incubated with secondary antibodies for 1hr at room
temperature, and washed with TBST (3 x 5min), and imaged using Amersham Typhoon
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(GE). Signal intensities were quantified using ImageJ and statistical significance was
determined using an unpaired Student’s t-test (N=3) (Excel).

Lifespan.
Synchronized day one adults were collected and used to perform lifespan analysis as
described92. Young adult nematodes were collected and divided between 6 OP50 seeded
NGM plates containing floxuridine (FUdR, RPI) to halt reproduction (100 µg/mL).
Individuals were counted every 1-2 days and scored as dead if there was no movement
after mechanical stimulation. Nematodes were scored as “censored” if their death was
caused by unnatural events such as drying out, internal hatching, or vulvar protrusion.
Nematodes were transferred to new plates every 2-3 days to avoid starvation. KaplanMeyer curves were generated followed by log-rank analysis using GraphPad Prism
version 9.0.0 (San Diego, California USA)(N≥120). A value of P<0.05 was considered
statistically significant. All experiments were performed at 20˚C and at least 3 times under
blinding conditions.

Length measurements.
Stemi 508 (ZEISS) stereomicroscope and Axiocam 208 color (ZEISS) were used at 10X
magnification to capture random images of each strain at various stages of development.
The software ZEN Digital Imaging for Light Microscopy (RRID:SCR_013672) was used
to take manual measurements of individual nematodes. Data shown represents the
average length of each strain during each stage of development (N≥3) ± SD. Statistical
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significance was calculated using unpaired Student’s t-test in GraphPad (Prism 9). A
value of P<0.05 was considered statistically significant.

Developmental Timeline.
Developmental timeline was examined using the wMicroTracker™ (WMT) from InVivo
Biosystems and the experimental design was adapted from a previous study93.
Synchronized L1 arrested nematodes from each strain were added to 95µL S-complete
supplemented with OP50 E. coli (OD600:0.07) in 8 wells of a clear U-bottom 96-well plate
(Corning) with about 100 nematodes per well. The plate was placed inside the WMT, and
activity was monitored for 72hrs at room temperature (~20˚C). The mean activity in each
30min time interval of 8 technical replicates for each strain was generated with the WMT
software and plotted using GraphPad (Prism). The data shown is the 2nd order smoothing
of the raw activity counts over 72hrs (N=8).

Food Consumption.
Food consumption was measured as described previously94 using liquid S-complete
medium with 100µg/mL Streptomycin and OP50 (OD600: 1-1.5) in black, optically clear
flat-bottom 96-well plates (Corning). 20-30 Age synchronized L1 larvae were washed and
placed into each well with 12 technical replicates per strain and the OD600 was measured
using the synergy MX plate reader (Biotek). The plates were then covered with a gas
permeable seal (BrandTech® Scientific, Inc.) and incubated at 20˚C. Every 24hrs, plates
were shaken at 1,200rpms for 25 minutes to resuspend the bacteria; the OD600 was
measured, and the plate was resealed and returned to 20˚C. On day 4 of adulthood, the
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number of nematodes in each well were counted to normalize changes in OD600. Daily
food consumption was determined by subtracting the OD600 of the test well from the
average OD600 of wells containing no nematodes (control), divided by the number of
individuals in the test well, and subtracted from the absorption of that well the previous
day. The data is represented as the average daily consumption each day (N=12) ±SD.
Statistical significance was calculated using an unpaired Student’s t-test in GraphPad
(Prism). A value of P<0.05 was considered statistically significant.

Pharyngeal pumping.
Pharyngeal pumping was manually counted using Stemi 508 (ZEISS) at 50X
magnification in 10s intervals to determine pumps per minute. Statistical significance for
each day was calculated using an unpaired Student’s t-test in GraphPad (Prism) and a
value of P<0.05 was considered statistically significant (N=15).

Paraquat treatment.
Paraquat was used to measure oxidative stress sensitivity as described previously95. 20
synchronized L4 or Day 1 adult nematodes from each strain were placed on 5 NGM plates
containing 100mM paraquat and seeded with OP50. Each individual nematode was
counted every hour for 25hrs and scored as dead or censored. Each Plate was counted
as a replicate within each strain and statistical differences at each timepoint was
calculated using an unpaired t-test (Prism 9). Experiments were performed twice under
blinding conditions. Values shown are mean survival ± SEM, (N=5). A Value of P<0.05
was considered statistically significant.
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Heat-shock treatment.
Heat-shock

(HS)

experiments

were

designed

based

on

the

methodological

considerations discussed previously96. For each strain, 120 age-synchronized, youngadult worms were divided between 6 OP50 seeded NGM plates (20 worms/plate) at room
temperature for each condition. Plates were placed in a 37°C incubator for either 2hrs or
2.5hrs then returned to 20°C for a 17hr recovery period. After recovery, the individual
nematodes were counted and scored as dead, paralyzed, or censored. Death was
characterized by absolutely no movement following mechanical stimuli, and paralysis was
characterized by the inability to move more than half its body length following mechanical
stimuli. Bar graphs represent the average amount of death or paralysis of 6 plates (20
nematodes each) ±SD (N=6). Unpaired Student’s t-tests were used to identify significant
differences between strains. A value of P<0.05 was considered statistically significant.
The 2hr and 2.5hr conditions were performed twice with separate populations, and
experiments were performed under blinding conditions.

Western blot – Ubiquitin.
Primary antibodies used to detect ubiquitin were purchased through Abcam and ABclonal
(anti-ubiquitin Ubi-1, ab7254; anti-βActin, AC026) and diluted 1:1000 in TBST+3% BSA.
The secondary antibodies used include IgG-HRP (Thermo, 32430) diluted 1:10,000 in
TBST+3%BSA and Alexa Fluor™ 488 (Thermo, A-11008) diluted 1:3000 in
TBST+3%BSA. To probe for HS induced ubiquitin accumulation, young adult nematodes
were incubated at 37˚C for 2hrs and 2.5hrs. 1hr after HS, 100 individual nematodes were
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transferred to 30µL M9 and placed at -80˚C for at least 15 minutes. Samples were then
thawed, mixed with 10µL LDS Sample Buffer (4X) (Invitrogen), and lysed by incubating
at 95˚C for 10min. Lysed samples were separated using NuPAGE® 4-12% Bis-Tris gels
(Invitrogen) and transferred to Immobilon-FL PVDF membranes (Millipore) using
NuPAGE® Transfer Buffer (Invitrogen) at room temperature (30V, 90min). Membranes
were blocked for 1hr at room temperature in TBST+3% BSA, briefly rinsed with TBST,
incubated with primary antibodies overnight at 4˚C, washed with TBST (3 x 5min),
incubated with secondary antibodies for 1hr at room temperature, and washed with TBST
(3 x 5min). HRP-labeled ubiquitin was detected using Pierce ECL-Plus Substrate
(Thermo) and imaged using G:BOX XX9 (Syngene). Fluorescent antibodies were imaged
using Amersham Typhoon (GE). Intensities and ratios were calculated using ImageJ
(NIH).Fold changes were calculated by determining the ratio between the HS conditions
and corresponding control for each strain. The data were analyzed using 2-way ANOVA
in GraphPad (Prism, N=2) A value of P≤0.05 was considered statistically significant.

Statistical analysis.
The data were analyzed using unpaired Student’s t-tests, 2-way ANOVA, and log-rank
tests (Prism). N-values are provided in each method. For all statistical analyses, a value
of P<0.05 was considered significant (*P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001).
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Supplementary Figures

Fig. S1. Molecular approach to gene editing of the C. elegans DNA using Crispr/Cas9 and its verifications
A. CRISPR approach showing guide RNA in yellow and region deleted in gray.
B. PCR genotyping showing amplification to each primer set. The CRISPR edited nematodes each
have a 317bp mutant band and do not have the 331bp wild type band and vice-versa.
C. On-target and off-target editing analysis showing deletion in targeted region and no variations in offtarget regions. Off-target regions were detected by finding regions that have a complimentary
nucleotide sequence with ≤4 mismatches to the guide RNA used to perform the gene editing in the
target region. The dashed line means no variations within 20bp of the off-target region identified.
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Figure S2. Native-PAGE western blot and full SDS-PAGE immunoblots shown in figure 1C.
A. Native-PAGE western blot probing for 20S α-subunits (Enzo, MCP231).
B. 20S α-subunits corresponding to Fig. 1C (Enzo, MCP231).
C. Tubulin bands used for loading control corresponding to Fig. 1 C (abcam, ab6161).
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Fig. S3. Full In-gel activity assay and western blot corresponding to Fig. 2C.
A. In-gel activity assay showing 20S and 26S Suc-LLVY-AMC peptidase activity after 30 minutes.
B. In-gel activity assay after incubation with 0.02% SDS for 30 minutes.
C. Native-PAGE immunoblot of 20S α-subunits (Enzo, MCP231).
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Fig. S4. In-vitro proteasome activity assay without normalization to MG132 corresponding to Figure 2.
A. Suc-LLVY-AMC peptidase activity with and without ATP ± MG132 (100µM). Values shown are the
mean ± SD (N=3)
B. Fluorescence polarization (FP) of FITC-Casein over 4hrs using 5ug lysate from each strain without
ATP (100µM MG132 used to inhibit proteasome activity). Values are the 2nd order smoothing of
the raw FP at each timepoint (N=3).
C. GFP fluorescence over time showing Ub4(lin)GFP-35 degradation ± MG132. Error bars represent
SD (N=3)
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Fig. S5. Ubiquitin accumulation after HS quantification corresponding to Figure 4E.
The high molecular weight ubiquitin (anti-ubiquitin Ubi-1, ab7254) signal was calculated from 2 separate
experiments and normalized to the loading control, actin (anti-βActin, AC026). HS induced high molecular
weight accumulation in each strain was normalized to the corresponding non-HS control (first 2 lanes) to
calculate fold change (FC). Statistics were performed using a 2-way ANOVA. Bar graph shows average FC
± SD (N=2); *P≤0.05.
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Dissertation conclusions
Proteostasis disruption is a critical driving force of aging and age-related disease
progression as it is implicated in almost every major hallmark of aging. Proteostasis
disruption occurs when proteins become damaged or misfolded and overwhelm the
protein quality control machinery leading to accumulation and aggregation of non-native
proteins. When proteins are damaged beyond repair or are no longer needed, they are
usually targeted for degradation by the ubiquitin proteasome system (UPS) which has
been shown to become less active with age. The mechanism behind proteasomal
inhibition is unclear, but here we have shown evidence that soluble oligomeric forms of
various neurodegenerative disease proteins can bind to and inhibit the proteasome by
stabilizing a closed-gate conformation. These oligomers are unable to inhibit a mutant
form of the 20S that has a constitutively open gate. Thus, we decided to pursue
introducing this open-gate construct in a multicellular organism to test its efficacy. By
directly editing the genome of C. elegans, we were able to generate the first complex
organism that expresses a hyperactive open-gate 20S proteasome. As predicted, this led
to a 20% increase in lifespan and significant resistance to oxidative and heat stress.
These studies show that targeting the proteasome to stimulate protein degradation in the
context of aging and disease is not only feasible but also protective and provides a solid
foundation for future discovery.
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Future directions
The data reported in this dissertation just scratches the surface of what we can discover
using this α3ΔN nematode strain. However, it provides the starting point for many
avenues of discovery.

Proteasome activity
It is important to note that the proteasome activity we reported for our mutant nematode
uses whole nematode lysates in vitro. The ideal approach to determine proteasome
mechanism is to use purified proteasomes. Although this α3ΔN mutant has been purified
and characterized in other species (i.e. yeast & mammalian cells)1,2, it would be useful to
confirm the mechanisms in our nematode strain. We could also measure the in vivo
activity by expressing a ubiquitin tagged GFP as has been done previously in nematodes
and mammalian cells.

Reproduction
An important reminder about nematode reproduction is that although a small fraction
(0.02%) of any given population are males, C. elegans exist primarily as hermaphrodites.
They produce both sperm and eggs and most of their progeny result from self-fertilization.
In our study, we reported a 90% decreased fecundity in our open-gate mutants, and this
phenotype alone provides several avenues for exploration. First, what is the root cause
of this drastic decrease? Is it due to dysfunctional gamete development, fertilization,
embryonic development, or something else? One observation that we do not report in our
primary study is that the α3ΔN mutant lays a higher ratio of oocytes (unfertilized eggs) to
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fertilized eggs compared to WT early in the reproductive period. Oocytes are soft and
circular in shape while fertilized eggs are more rigid and oval shaped, so it is fairly simple
to differentiate between the two. However, when we preliminarily determined the total
amount of oocytes and eggs laid for each strain, α3ΔN had significantly less compared to
WT. Also, virtually all visibly fertilized eggs laid by α3ΔN hatched into viable offspring
suggesting that fertilization and embryonic development occurs normally. Therefore, I
hypothesize that gametogenesis might be the culprit here. Nematodes differ from
mammals in that they produce a finite number of sperm during development rather than
oocytes. In nematode hermaphrodites at larval stage 3, the first few germ cells that enter
meiosis differentiate into sperm cells, and starting at larval stage 4, the rest develop into
oocytes throughout reproduction3. This means there is only about an 8-hour timeframe C.
elegans have to produce sperm so anything that interrupts gamete formation in this
timeframe could severely impact reproductive fitness. A previous study showed that
proteasome activity is involved in the regulation of germ cell proliferation and the decision
to enter meiosis for gamete formation4. Given the proteasome’s role here, it is probable
that a hyperactive proteasome would impact this decision pathway.

We also briefly mentioned that more of what we predict to be PA200 is associating with
the proteasome in our gateless mutants. It is well known that PA200 plays an important
role in mammalian spermatogenesis5 so this observation could shed light on more clues
as well. However, it is possible that what we’ve indicated as pa200 is actually a PA28γ,
which has also been implicated in male fertility6. We have not been able to locate an
antibody that can identify the C. elegans homologs of either protein but are in the process

153

of developing them now. Determining which protein is associating with the open gate
would shed light on a possible compensatory mechanism happening and the normal
mechanism of either one of these proteins.

Oxidative stress resistance
Our data shows clear evidence that nematodes expressing an open-gate proteasome are
resistant to the oxidative stress inducing toxin, paraquat. It’s important to note that just
because α3ΔN is resistant to paraquat doesn’t mean that they are significantly more
resistant to oxidative stress in general. It is possible that paraquat causes less oxidative
stress in α3ΔN compared to WT. Paraquat increases ROS production through inhibition
of the mitochondrial ETC. Therefore, if open-gate proteasome expression decreases the
functionality of the mitochondria, paraquat may not cause as much of an increase in ROS
production compared to WT. Preliminary data gathered using a Seahorse Bioanalyzer
showed decreased oxygen consumption rate for α3ΔN suggesting disrupted
mitochondrial respiration. However, further optimization is needed to determine the
reliability of this observation. To rule this out, there are other compounds (i.e. Juglone
and H2O2) we could use to test oxidative stress resistance. Although the mechanism is
different from paraquat, juglone also increases ROS through the mitochondria. However,
H2O2 is a ROS itself which would bypass the potential mitochondrial mitochondria issue.

‘Omics analyses
A global proteomic analysis found a significant decrease in sHSPs in our open gate
nematodes. This contrasts with many other long-lived mutants which are characterized
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by an increase in sHSPs7–12. Most other long-lived mutants are characterized by a general
increase in proteostasis health, and this is thought to be due to the upregulation of several
stress response proteins (i.e., chaperones and antioxidants). The downregulation of
sHSPs combined with the extended lifespan and resistance to proteotoxic stress in α3ΔN
suggests that this mutant has an overall healthier and more resilient proteome and that
these benefits are mediated by a hyperactive proteasome and not stress protein
upregulation. Our lab is currently in the process of analyzing transcriptomics to gain a
better perspective on what exactly is going on physiologically in these nematodes. We
also found significant alterations in several energy metabolism pathways including
glycolysis, fatty acid oxidation, and oxidative phosphorylation. The next step here would
be to plan a metabolomic study to determine metabolizes present under certain conditions
as well as lipid content. This would give us a clearer understanding of the true metabolic
changes happening in our open gate nematodes and whether the life extension we see
has something to do with a dietary restriction phenotype. We performed a comparative
analysis between the proteome of our nematode and that of two other food restricted
models and didn’t observe any significant overlap in differential protein expression.
However, it’s possible that there are some components of our nematode that mimic
specific features of a starvation model, and this could help pinpoint a specific pathway
responsible for life extension in both. The ‘Omic studies that we have conducted and the
ones that are currently underway will provide many answers that will surely lead to even
more questions, but I’m looking forward to the discoveries that will be made using this
model and the value it will add to both the proteasome and aging field.
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